Rockley Photonics (RKLYQ) S-1 9 Sep 21 IPO registration Financial data

Cover Page

Cover Page	6 Months Ended
	Jun. 30, 2021
Document Information [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	Rockley Photonics Holdings Limited
Entity Central Index Key	0001852117
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Mar. 11, 2021	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 35,395		$ 19,228	$ 20,904
Accounts receivable	2,411		4,925	6,383
Other receivables	23,037		18,024	15,949
Prepaid expenses	7,724		1,605	1,763
Other current assets	258		609	1,757
Total current assets	68,825		44,391	46,756
Property, equipment, and finance lease right-of-use assets, net	8,170		6,182	7,280
Equity method investment	4,711		5,202	1,486
Intangible assets, net	3,048		3,048	0
Other non-current assets	11,715		1,607	2,212
Total assets	96,469		60,430	57,734
Current liabilities
Trade payables	8,692		4,413	7,373
Accrued expenses	12,104		10,395	6,852
Long term debt, current portion	0		0	1,952
Other current liabilities	1,020		998	3,569
Total current liabilities	21,816		15,806	19,746
Long-term debt	194,328		74,804	0
Other long-term liabilities	2,719		1,127	1,729
Total liabilities	218,863		91,737	21,475
Commitments and contingencies (Note 13)
Shareholders' deficit
Ordinary Shares, $0.00001 par value; 55,982,833 and 38,312,233 authorized as of December 31, 2020 and 2019, respectively; 33,637,762 and 33,337,115 issued and outstanding as of December 31, 2020 and 2019, respectively			0	0
Additional paid-in-capital	205,823		201,576	188,865
Accumulated deficit	(328,217)		(232,883)	(152,606)
Total shareholders' deficit	(122,394)		(31,307)	36,259
Total liabilities and Shareholders' deficit	96,469		$ 60,430	$ 57,734
Rockley Photonics Holdings Limited
Current assets
Receivable from affiliate	50	$ 50
Total current assets	50	50
Total assets	50	50
Shareholders' deficit
Ordinary shares and additional paid-in capital (Note 2)	50	50
Total shareholders' deficit	$ 50	$ 50

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 377	$ 0
Ordinary shares, par value (in dollars per share)		$ 0.00001	$ 0.00001
Ordinary shares authorized (in shares)	55,982,833	55,982,833	38,312,233
Ordinary shares issued (in shares)	33,825,620	33,637,762	33,337,115
Ordinary shares outstanding (in shares)	33,825,620	33,637,762	33,337,115

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 2,195	$ 7,881	$ 3,966	$ 14,544	$ 22,343	$ 20,492
Cost of revenue	4,549	6,522	8,283	13,085	24,240	30,705
Gross profit	(2,354)	1,359	(4,317)	1,459	(1,897)	(10,213)
Operating expenses:
Selling, general and administrative expenses	6,715	3,604	14,020	7,249	20,260	13,306
Research and development expenses	17,551	7,746	33,531	16,217	35,900	22,303
Total operating expenses	24,266	11,350	47,551	23,466	56,160	35,609
Loss from operations	(26,620)	(9,991)	(51,868)	(22,007)	(58,057)	(45,822)
Other income (expense):
Forgiveness of Paycheck Protection Program loan	2,860		2,860	0
Interest expense, net	(179)	(34)	(326)	(74)	(189)	(747)
Equity method investment loss	(597)	(102)	(760)	(252)	(1,274)	(1,281)
Change in fair value of debt instruments	(6,008)	312	(45,661)	(2,222)	(20,163)	(2,969)
Gain (loss) on foreign currency	97	(108)	631	(1,654)	(25)	280
Total other income (expense)	(3,827)	68	(43,256)	(4,202)	(21,651)	(4,717)
Loss before income taxes	(30,447)	(9,923)	(95,124)	(26,209)	(79,708)	(50,539)
Provision for income tax	110	80	210	220	569	311
Net loss and comprehensive loss	$ (30,557)	$ (10,003)	$ (95,334)	$ (26,429)	$ (80,277)	$ (50,850)
Net loss per share:
Net loss per share, Basic and diluted	$ (0.90)	$ (0.30)	$ (2.82)	$ (0.79)	$ (2.39)	$ (1.62)
Weighted-average shares outstanding:
Weighted-average shares outstanding, Basic and diluted	33,922,973	33,625,899	33,850,070	33,554,441	33,604,752	31,406,127

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Deficit - USD ($) $ in Thousands	Total	Ordinary Shares	Ordinary Shares and Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2018		29,215,692
Beginning balance at Dec. 31, 2018	$ 23,906		$ 125,662	$ (101,756)
Increase (Decrease) in Stockholders' Equity
Net loss	$ (50,850)			(50,850)
Exercise of stock options (in shares)	24,750	24,750
Exercise of stock options	$ 33		33
Exercise of warrants (in shares)		2,757
Exercise of warrants	19		19
Issuance of warrants	2,878		2,878
Stock-based compensation	6,229		6,229
Non-cash warrants issued as dividends	(1,838)		(1,838)
Extinguishment of 2019 Convertible Loan Note	18,244		18,244
Ordinary share issuance for acquisition of in-process research and development (Shares)		4,093,916
Ordinary share issuance for acquisition of in-process research and development (Value)	37,638		37,638
Ending balance (in shares) at Dec. 31, 2019		33,337,115
Ending balance at Dec. 31, 2019	36,259		188,865	(152,606)
Increase (Decrease) in Stockholders' Equity
Net loss	(16,426)			(16,426)
Exercise of stock options (in shares)		3,730
Exercise of stock options	20		20
Exercise of warrants (in shares)		5,523
Exercise of warrants	7		7
Stock-based compensation	1,644		1,644
Ordinary share issuance, net of issuance costs (in shares)		147,432
Ordinary share issuance, net of issuance costs	2,087		2,087
Ending balance (in shares) at Mar. 31, 2020		33,493,800
Ending balance at Mar. 31, 2020	23,591		192,623	(169,032)
Beginning balance (in shares) at Dec. 31, 2019		33,337,115
Beginning balance at Dec. 31, 2019	36,259		188,865	(152,606)
Increase (Decrease) in Stockholders' Equity
Net loss	(26,429)
Ending balance (in shares) at Jun. 30, 2020		33,493,800
Ending balance at Jun. 30, 2020	16,007		195,042	(179,035)
Beginning balance (in shares) at Dec. 31, 2019		33,337,115
Beginning balance at Dec. 31, 2019	36,259		188,865	(152,606)
Increase (Decrease) in Stockholders' Equity
Net loss	$ (80,277)			(80,277)
Exercise of stock options (in shares)	7,813	7,813
Exercise of stock options	$ 42		42
Exercise of warrants (in shares)		5,523
Exercise of warrants	7		7
Issuance of warrants	360		360
Stock-based compensation	8,043		8,043
Non-cash warrants issued as dividends	0
Ordinary share issuance, net of issuance costs (in shares)		147,432
Ordinary share issuance, net of issuance costs	1,961		1,961
Ordinary share issuance for acquisition of in-process research and development (Shares)		139,879
Ordinary share issuance for acquisition of in-process research and development (Value)	2,298		2,298
Ending balance (in shares) at Dec. 31, 2020		33,637,762
Ending balance at Dec. 31, 2020	(31,307)		201,576	(232,883)
Beginning balance (in shares) at Mar. 31, 2020		33,493,800
Beginning balance at Mar. 31, 2020	23,591		192,623	(169,032)
Increase (Decrease) in Stockholders' Equity
Net loss	(10,003)			(10,003)
Stock-based compensation	2,545		2,545
Ordinary share issuance, net of issuance costs	(126)		(126)
Ending balance (in shares) at Jun. 30, 2020		33,493,800
Ending balance at Jun. 30, 2020	16,007		195,042	(179,035)
Beginning balance (in shares) at Dec. 31, 2020		33,637,762
Beginning balance at Dec. 31, 2020	(31,307)		201,576	(232,883)
Increase (Decrease) in Stockholders' Equity
Net loss	(64,777)			(64,777)
Exercise of stock options (in shares)		87,244
Exercise of stock options	137		137
Exercise of warrants (in shares)		23,278
Issuance of warrants	263		263
Stock-based compensation	1,725		1,725
Ending balance (in shares) at Mar. 31, 2021		33,748,284
Ending balance at Mar. 31, 2021	(93,959)		203,701	(297,660)
Beginning balance (in shares) at Dec. 31, 2020		33,637,762
Beginning balance at Dec. 31, 2020	(31,307)		201,576	(232,883)
Increase (Decrease) in Stockholders' Equity
Net loss	$ (95,334)
Exercise of stock options (in shares)	164,580
Ending balance (in shares) at Jun. 30, 2021		33,825,620
Ending balance at Jun. 30, 2021	$ (122,394)		205,823	(328,217)
Beginning balance (in shares) at Mar. 31, 2021		33,748,284
Beginning balance at Mar. 31, 2021	(93,959)		203,701	(297,660)
Increase (Decrease) in Stockholders' Equity
Net loss	(30,557)			(30,557)
Exercise of stock options (in shares)		77,336
Exercise of stock options	146		146
Stock-based compensation	1,976		1,976
Ending balance (in shares) at Jun. 30, 2021		33,825,620
Ending balance at Jun. 30, 2021	$ (122,394)		$ 205,823	$ (328,217)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (95,334)	$ (26,429)	$ (80,277)	$ (50,850)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property, equipment and finance lease right-of-use assets	1,999	1,395	2,787	1,948
Gain on disposal of property and equipment		(98)	(107)	(24)
Bad debt expense	377
Stock-based compensation	3,701	4,189	8,043	6,229
Change in equity-method investment	491	252
Change in fair value of debt instrument	45,661	2,222	20,163	2,969
Forgiveness of Paycheck Protection Program loan	(2,860)	0
Changes in operating assets and liabilities:
Accounts receivable	2,137	(1,382)	1,458	(618)
Other receivables	(5,013)	8,602	(2,074)	(3,246)
Prepaid expenses and other current assets	(5,769)	1,263	1,307	(1,030)
Other non-current assets	(1,733)	357	604	(672)
Trade payables	(130)	(4,347)	(3,126)	2,464
Accrued expenses	402	1,708	3,537	2,214
Other current and long-term liabilities	1,614	(838)	(1,943)	2,236
Amortization of debt discount and issuance costs				268
Equity method investment loss	760	252	1,274	1,281
Non-cash interest on convertible loan notes			0	286
Net cash used in operating activities	(54,457)	(13,106)	(48,354)	(36,556)
Cash flows from investing activities:
Purchase of property and equipment	(2,822)	(650)	(1,416)	(2,973)
Payment for asset acquisition	(500)		(250)
Proceeds from disposal of property and equipment			0	142
Investment in equity method investee		(2,500)	(4,990)
Net cash used in investing activities	(3,322)	(3,150)	(6,656)	(2,831)
Cash flows from financing activities:
Proceeds from convertible loan notes	76,723	12,250	51,781	15,000
Principal payments on long-term debt		(1,952)	(1,952)	(3,534)
Proceeds from issuance of ordinary shares, net of issuance costs		1,961	1,961	38,639
Proceeds from Paycheck Protection Program loan		2,860	2,860
Proceeds from exercise of options	283	20	42	33
Proceeds from the exercise of warrants	233	7	7
Proceeds from issuance of warrants	263		360
Debt issuance costs incurred	(3,556)		(494)
Principal payments on finance lease		(1,231)	(1,231)	(1,205)
Net cash provided by financing activities	73,946	13,915	53,334	48,933
Net increase (decrease) in cash and cash equivalents	16,167	(2,341)	(1,676)	9,546
Cash and cash equivalents:
Beginning of period	19,228	20,904	20,904	11,358
End of period	$ 35,395	$ 18,563	$ 19,228	$ 20,904

Description of Business and Sig

Description of Business and Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Significant Accounting Policies	1. Description of Business and Significant Accounting Policies Description of Business Rockley Photonics Limited and its subsidiary entities (together, “we”, “us”, “our”, “Rockley” or, “the Company”) was founded in 2013 in the United Kingdom. We specialize in the research and development of integrated silicon photonics chipsets and have developed a versatile, application specific, third-generation silicon photonics platform specifically designed for the optical integration challenges facing numerous mega-trend markets. We have partnered with multiple tier-1 Basis of Presentation and Preparation The accompanying unaudited condensed consolidated financial statements have been prepared by the Company, and reflect all adjustments, consisting only of normal recurring adjustments, that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations, comprehensive income, cash flows and shareholders’ equity for the interim periods presented. The statements have been prepared in accordance with GAAP for interim financial information. Accordingly, these statements do not include all information and footnotes required by GAAP for annual consolidated financial statements, and should be read in conjunction with our audited consolidated financial statements and notes thereto in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2020 included in the Rockley Photonics Holdings Limited’s Registration Statement on Form S-4 No. 333-255019), The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include, but are not limited to, revenue recognition, reserves and allowances; valuation of intangibles; product warranties; employee compensation and benefit accruals; stock-based compensation; loss contingencies; income taxes and fair value measurements. Actual results could differ materially from those estimates. Management’s estimates include, as applicable, the anticipated impacts of the COVID-19 Going Concern The Company has incurred net losses since inception, has an accumulated deficit of $328.2 million as of June 30, 2021 and negative cash flow from operations of $54.5 million for the six months ended June 30, 2021 and expects to incur losses from operations for the foreseeable future. As of June 30, 2021, the Company had cash and cash equivalents of approximately $35.4 million. The Company’s ability to meet its obligations in the ordinary course of business is dependent on its ability to obtain additional financing. As a result, there is substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Our future liquidity needs, and ability to address those needs, will largely be determined by our ability to obtain additional financing on terms acceptable to us. We will continue to seek additional capital through the sale of debt or equity, or other arrangements, however, there can be no assurance that we will be able to raise Global Pandemic The COVID-19 COVID-19 The COVID–19 pandemic has adversely impacted our operational efficiency and caused delays in operational activities. During the second quarter of 2021, we continue to take cautious steps to protect our workforce, support community efforts, and follow local government guidelines. Certain key laboratory employees and facilities have continued internal testing and laboratory work to the extent necessary to service customer commitments. The remaining non-essential Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU 2018-13, On June 16, 2016, the FASB issued ASU No. 2016-13, available-for-sale In August 2020, the FASB issued ASU 2020-06, 470-20) 815-40): Accounting Pronouncements Issued but Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, simplifies areas including franchise taxes that are partially based on income, transactions with a government that result in a step up in the tax basis of goodwill, the incremental approach for intraperiod tax allocation, interim period income tax accounting for year-to-date laws 2019-12 2020	1. Description of Business and Significant Accounting Policies Description of Business Rockley Photonics Limited and its subsidiaries (together, “we”, “us,” “our,” or, “the Company”) was founded in 2013 in the United Kingdom. We specialize in the research and development of integrated silicon photonics chipsets and have developed a versatile, application specific, third-generation silicon photonics platform specifically designed for the optical integration challenges facing numerous mega-trend markets. We have partnered with multiple tier-1 Going Concern The Company has incurred net losses since inception, has an accumulated deficit of $232.9 million as of December 31, 2020 and negative cash flow from operations of $48.4 million for the year ended December 31, 2020 and expects to incur losses from operations for the foreseeable future. As of December 31, 2020, the Company had cash and cash equivalents of approximately $19.2 million. The Company’s ability to meet its obligations in the ordinary course of business is dependent on its ability to obtain additional financing. As a result, there is substantial doubt about our ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Our future liquidity needs, and ability to address those needs, will largely be determined by its ability to obtain additional financing on terms acceptable to us. We will continue to seek additional capital through the sale of debt or equity, or other arrangements, however, there can be no assurance that we will be able to raise additional capital when needed or under acceptable terms, if at all. The sale of additional equity may dilute existing shareholders and newly issued shares may contain senior rights and preferences compared to currently outstanding Ordinary Shares. Issued debt securities may contain covenants and limit our ability to pay dividends or make other distributions to shareholders. If we are unable to obtain additional financing, operations may be scaled back or discontinued. Global Pandemic On March 11, 2020, the World Health Organization characterized the outbreak of COVID-19 COVID-19 “stay-at-home” Consistent with the actions taken by governmental authorities, we have taken appropriately cautious steps to protect our workforce and support community efforts. As part of these efforts and in accordance with applicable government directives, we reduced on-site on-site COVID-19 and regular testing of its employees for COVID-19. non-essential The COVID-19 Basis of Presentation The consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Principles of Consolidation The consolidated financial statements include Rockley Photonics Limited and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates and assumptions, including those related to (i) revenue recognition including variable consideration, (ii) useful lives and recoverability of property and equipment and long-lived assets, (iii) incremental borrowing rates on the Company’s finance and operating leases, (iv) valuation of our convertible loan notes, (v) valuation allowances for income taxes, (vi) stock-based compensation including the valuation of Ordinary Shares, (vii) valuation of warrants and (viii) contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could materially differ from these estimates, including impacts from the COVID-19 Cash and Cash Equivalents Cash and cash equivalents include short-term, highly liquid investments with an original maturity of three months or less. Property and Equipment, Net Property and equipment are recorded at cost and presented net of accumulated depreciation and amortization. Significant additions or improvements extending the useful life of an asset are capitalized, while repairs and maintenance costs are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the term of the lease or the useful life of the assets. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the related assets. Computer equipment 3 years Lab equipment 3 years Furnitures and fixtures 4 years Leasehold improvements Shorter of the lease term and the useful life Impairment of Long-Lived Assets We evaluate our long-lived assets, such as property and equipment, and right-of-use The Company tests other intangible assets not subject to amortization for impairment annually and more frequently if events or changes in circumstances between annual tests indicate that it is more likely than not that the asset is impaired. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets. To date, no such impairment losses have been recorded. Revenue Recognition We generate our revenue principally from development services, which entails developing the customer-specific designs of photonics chips. Revenue is recognized when control of promised goods and services are transferred to customers in an amount that reflects the expected consideration in exchange for those products and services. This principle is achieved by applying the following five-step approach: • Identification of the contract with a customer – • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations in the contract • Recognition of revenue when or as performance obligations are satisfied Contract balances 30-45 Costs to obtain and fulfill a contract – Foreign Currency Transactions The Company’s reporting currency is the U.S. dollar and the functional currency of the Company’s foreign subsidiaries is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into the functional currency with any related gain or loss recorded in earnings. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in realized and unrealized losses/(gains) on foreign currency in the accompanying consolidated statements of operations and comprehensive loss. Segment Information Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the CODM. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, the Company determined that it has one operating and reportable segment. Net Loss Per Share Basic earnings per share is calculated using our weighted-average outstanding Ordinary Shares. Diluted earnings per share is calculated using our weighted-average outstanding Ordinary Shares including the dilutive effect of outstanding equity instruments as determined under the treasury stock method. For periods in which we report net losses, diluted net loss per ordinary share attributable to ordinary stockholders is the same as basic net loss per ordinary share attributable to ordinary stockholders, because all potentially dilutive Ordinary Shares are anti-dilutive. Concentration of Risk Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable. We maintain cash balances at financial institutions that management believes are high-credit, quality financial institutions, where deposits, at times, exceed the Federal Deposit Insurance Corporation limits. Accounts Receivable Accounts receivable is recorded at the invoiced amount and do not bear interest. We assess the need for an allowance for doubtful accounts based upon an analysis of past credit history and the current financial condition of its customers, as well as the consideration of expected trends based upon characteristics of the accounts and general economic conditions. Account balances are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts is insignificant as of December 31, 2020 and 2019. Equity Method Investments Equity method investments are all entities over which we have significant influence but not control or joint control. Under the equity method of accounting, the investments are initially recognized at cost and adjusted thereafter to recognize the Company’s share of the post-acquisition profits or losses of the investee in the consolidated statement of operations and comprehensive loss. Earnings and losses of equity method investments are based on the most recently available financial statements of the investee. Basis differences between the cost of an equity method investment and the underlying equity in the long-lived assets are amortized over the estimated economic useful life of the underlying long-lived asset. We periodically review our equity method investments for impairment and record a reduction in the carrying value, if and when necessary. To date, no such impairment losses have been recorded. Stock-Based Compensation We measure compensation expense for all stock-based awards based on the estimated fair value of the awards on the date of grant. Compensation expense is generally recognized as expense on a straight-line basis over the service period based on the vesting requirements. We recognize forfeitures as they occur. We estimate the fair value of stock options granted to employees using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (i) the fair value of Ordinary Shares, (ii) the expected stock price volatility, (iii) the expected term of the award, (iv) the risk-free interest rate and (v) expected dividends. We measure nonemployee awards at their fair value on the adoption date of ASU No. 2018-07. No. 2018-07 We granted options and restricted stock units which vest on the satisfaction of both a specific performance condition and a service-based condition. Warrants We determine the accounting classification of warrants, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, 480-10, 815-40, 815-40, 815-40 We issue warrants to purchase Ordinary Shares for goods and services received and these warrants are measured at their fair values upon issuance. Where vendors are issued warrants, the fair value of the services are determined by the fair value of the warrants issued. This fair value is measured at the grant date and excludes the impact of non-market paid-in We may also issue warrants to purchase Ordinary Shares in conjunction with equity financing rounds. Such warrant issuances are recognized as equity issuance costs, with a corresponding credit in additional paid-in paid-in We issued the liability classified warrants during the year ended December 31, 2020 that are embedded with the 8.0% Convertible Notes. Refer to Note 7, Long Term Debt for details. Leases Our lease portfolio is comprised of two major classes: real estate leases, which are the majority of our leased assets, are accounted for as operating leases and a manufacturing equipment lease accounted for as a finance lease on the consolidated balance sheet. We classify leases as either operating or financing. We determine if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all the economic benefits from and have the ability to direct the use of the asset. Operating lease assets are included under other non-current right-of-use ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments is used. The operating lease ROU asset includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease We elected, as an accounting policy for leases of real estate, to account for lease and non-lease Variable payments, such as common area charges, maintenance, insurance and taxes, are primarily based on the amount of space occupied. These payments in the Company’s leases are not dependent on an index or a rate and are excluded from the measurement of the lease liabilities and recognized in the consolidated statements of operations and comprehensive loss in the period in which the obligation for those payments is incurred. The Company remeasures lease payments when the contingency underlying such variable payments is resolved such that some or all of the remaining payments become fixed. Cost of Revenue Our cost of revenue consists of costs related to the Company’s development services which includes cost of materials, cost associated with packaging and assembly, testing and shipping, cost of personnel, including stock-based compensation, and equipment associated with manufacturing support, logistics and quality assurance, overhead and occupancy costs. Research and Development Expenses Research and development expense consists primarily of personnel costs for engineers and third parties engaged in the design and development of products, software and technologies, including salary, bonus and share-based compensation expense, project material costs, services and depreciation. The Company expenses research and development costs as they are incurred . Selling, General and Administrative Expenses Selling, general and administrative expenses consist of human capital related expenses for employees involved in general corporate functions, including executive management and administration, accounting, finance, tax, legal, information technology, marketing, and human resources; depreciation expense and rent relating to facilities; travel costs; professional fees; and other general corporate costs. Human capital expenses primarily include salaries, benefits, bonuses and stock-based compensation. As we continue to grow as a company, we expect that our selling, general and administrative costs will increase on an absolute dollar basis. Fair Value of Financial Instruments and Fair Value Measurements The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: Level 1 Inputs: Unadjusted quoted prices for identical assets or instruments in active markets. Level 2 Inputs: Quoted prices for similar instruments in active markets and quoted prices for identical or similar instruments in markets that are not active and model derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 Inputs: Significant inputs into the valuation model are unobservable. As permitted under the FASB, ASC 825, Financial Instruments (“ASC 825”) Fair value is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not available, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments’ complexity. For debt instruments for which we have not elected fair value accounting (i.e. paycheck protection program), fair value is based on the present value of expected future cash flows and assumptions about the then-current market interest rates as of the reporting period and the creditworthiness of the Company. The carrying value of these debt instruments approximates fair value as the stated interest rate approximates market rates currently available to us. For all debt instruments, including any for which we have elected fair value accounting, the Company classifies interest that has been accrued during each period as Interest expense on the consolidated statements of operations and comprehensive loss. The recorded amounts of cash, accounts receivable, trade payable, and accrued expenses and other liabilities approximate the fair values principally because of their short-term nature. Income Taxes Deferred income taxes are provided on a liability method, whereby deferred income tax assets are recognized for deductible temporary differences, operating losses, and tax loss carryforwards, and deferred income tax liabilities are recognized for taxable temporary differences. Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their tax bases and are stated at enacted tax rates expected to be in effect when taxes are actually paid or recovered. Deferred income tax assets are reduced by a valuation allowance when, considering all sources of taxable income, in the opinion of management, it is more likely than not that some portion or all of the deferred income tax assets will not be realized. Deferred income tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company recognizes the income tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by taxing authorities, based on the technical merits of the position. The income tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Recently Adopted Accounting Pronouncements In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (Topic 815) 2018-02 In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (“Topic 820”): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement Accounting Pronouncements Issued but Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, 2019-12 On June 16, 2016, the FASB issued ASU No. 2016-13, available-for-sale non-public

Organization and Background

Organization and Background	6 Months Ended
	Jun. 30, 2021
Rockley Photonics Holdings Limited
Organization and Background	1. Organization and Background Rockley Photonics Holdings Limited (“HoldCo”, “we”, “us”, or “our”) was incorporated in the Cayman Islands with limited liability on March 11, 2021. As more fully described below, on August 11, 2021, HoldCo completed a merger with SC Health Corporation and Rockley Photonics Limited (“Rockley”), with Rockley surviving the merger as a wholly-owned subsidiary of HoldCo (the “Business Combination”). Immediately following the completion of the Business Combination and the related organizational transactions on August 11, 2021, HoldCo received $168.0 million in gross proceeds. Rockley will operate, conduct and control all of the business and affairs of HoldCo. SC Health and the shareholders of Rockley hold approximately 1.4% and 82.4% ownership interest in Rockley Photonics Holdings Limited, respectively. Basis of Presentation Our balance sheets have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). Statements of income, shareholders’ equity and cash flows have not been presented because, as of March 11, 2021 and through to June 30, 2021, we have not engaged in any business or other activities except in connection with our formation.

Fiscal 2020 Asset Acquisition

Fiscal 2020 Asset Acquisition	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Fiscal 2020 Asset Acquisition	2. Fiscal 2020 Asset Acquisition On November 25, 2020, we acquired certain technologies from TruTouch Technologies, Inc. (“Trutouch”). The consideration for the purchased technology was $3.1 million and consisted of $0.8 million in cash and $2.3 million in equity. The cash payments consisted of $0.3 million paid prior to the close of the transaction, and an additional $0.5 million to be paid in April 2021. The equity component of the consideration was 139,879 shares of ordinary stock in Rockley Photonics Limited, with a fair value of $16.43 per share or $2.3 million in total. We accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified asset, in-process 2017-1. development activities and will be incorporated in efforts and milestones to be undertaken by the Company to design and develop a new application in order to expand its presence in the healthcare and well-being markets (which the Company has determined to be the alternative future use of the asset). The IPR&D asset is reported as an indefinite-lived intangible asset and subject to impairment whenever events or changes in circumstances indicate that the carrying amount of the asset might not be recoverable. Upon completion of our new product development cycle that incorporates Trutouch technology, the IPR&D asset will be amortized over the useful life of the developed technology that underpins our product. In the event the Company abandons the project, the entire IPR&D asset will be written off in full.

Revenue Recognition

Revenue Recognition	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	2. Revenue Recognition Disaggregation of Revenue The following table depicts the disaggregation of revenue by geography, consistent with how we evaluate its financial performance (in thousands): Three Months Ended June 30 Six Months Ended June 30, 2021 2020 2021 2020 United States $ 2,195 $ 5,423 $ 3,966 $ 12,086 Rest of World $ — $ 2,458 $ — $ 2,458 Total revenue $ (2,195 ) $ 7,881 $ 3,966 $ 14,544 Significant Customers The following tables summarize our significant customers as of June 30, 2021 and December 31, 2020 and for the three and six months ended June 30, 2021 and 2020: Revenue Three Months Ended June 30 Six Months Ended June 30, 2021 2020 2021 2020 (Unaudited) (Unaudited) Customer A 100 % 69 % 100 % 83 % Customer B — % 31 % — % 17 % Accounts Receivable As of June 30, 2021 December 31, 2020 Customer A 81 % 33 % Customer B 17 % 67 %	3. Revenue Recognition We satisfy performance obligations at a point in time for the development services since the customers do not simultaneously receive and consume the benefits, we do not create or enhance an asset that the customer controls, and we do not have an enforceable right to payment for the performance completed to date. The contracts also contain substantive acceptance terms for each milestone due to its complexity. Revenue is recognized at the time the related performance obligation is satisfied with the transfer of a promised good or service to a customer, e.g., upon achievement of the milestone and acceptance by the customer. Disaggregation of Revenue and Revenue Recognition The following table depicts the disaggregation of revenue by geography, consistent with how we evaluate its financial performance (in thousands): December 31, 2020 2019 United States $ 17,037 $ 13,783 Rest of World 5,306 6,709 Total revenue $ 22,343 $ 20,492 Significant Customers The following is our significant customers as of and for the years ended December 31, 2020 and 2019: Revenue Accounts December 31, December 31, 2020 2019 2021 2020 Customer A 76 % 67 % 33 % 55 % Customer B 24 % 33 % 67 % 45 %

Equity Method Investment

Equity Method Investment	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	3. Equity Method Investment As of June 30, 2021 and December 31, 2020, we held an investment in Hengtong Rockley Technology Co., Ltd (“HRT”) and we appointed two of the HRT’s five board members. HRT manufactures and sells optical fiber transceivers based on silicon photonics chipsets. HRT has share capital consisting solely of Ordinary Shares. We hold 24.9% of HRT’s Ordinary Shares, which is the same as the proportion of its voting rights. We consider HRT to be a variable interest entity upon which the Company does exercise significant influence, but the Company concluded it does not control the investment. Accordingly, the investment in HRT is accounted for under the equity method. We elected to use a three-month lag to record our share of HRT’s results. See Note 11, Related Party Transactions for details on the Company’s transactions with HRT. The following table summarizes our investment in HRT for the six months ended June 30, 2021 (in thousands): June 30, 2021 (Unaudited) Beginning balance $ 5,202 Investment in HRT — Remeasurement gain on HRT 269 Share of loss of HRT (760 ) Ending balance $ 4,711 Our maximum exposure to loss as a result of our involvement with HRT is limited to the balance of our investment.	4. Investments As of December 31, 2020 and 2019, we held an investment in Hengtong Rockley Technology Co., Ltd (“HRT”) and have appointed two of their five board members. HRT manufactures and sells optical fiber transceivers based on silicon photonics chipsets. HRT has share capital consisting solely of Ordinary Shares. We hold 24.9% of HRT’s Ordinary Shares, which is the same as the proportion of its voting rights. We consider HRT to be a variable interest entity upon which it does exercise significant influence, but the Company concluded it does not control the investment. Accordingly, the investment in HRT is accounted for under the equity method. We have made the election to use a three-month lag to record our share of HRT’s results. See Note 12, Related Party Transactions for details of the Company’s transactions with HRT. For the years ended December 31, 2020 and 2019, the accompanying consolidated balance sheets and statements of operations and comprehensive loss reflected the following (in thousands): December 31, 2020 2019 As of January 1, $ 1,486 $ 2,767 Investment in HRT 4,990 — Share of loss of HRT (1,274 ) (1,281 ) As of December 31, $ 5,202 $ 1,486

Fair Value Measurements

Fair Value Measurements	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements Our financial assets are considered Level 1 in the fair value hierarchy and measured at fair value, were as follows (in thousands): As of June 30, December 31, (Unaudited) Assets Cash equivalents Money market funds $ 11,316 $ 11,516 All of our financial liabilities are considered Level 3 in the fair value hierarchy, where inputs to the valuation techniques used to measure fair value were considered unobservable. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the liability. The financial liabilities subject to fair value measurement on a recurring basis, were as follows (in thousands): As of June 30, December 31, (Unaudited) Financial Liabilities 3.00% – 2020 Convertible Notes $ 36,214 $ 32,106 8.00% – 2020 Convertible Notes 17,038 14,789 2020 Term Facility Loan 39,970 25,049 5.00% – $50.0 Million Convertible Notes 11,220 — 5.00% – $25.0 Million Convertible Notes 43,070 — 5.00% – $30.0 Million Convertible Notes 46,816 — Total financial liabilities $ 194,328 $ 71,944 Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the condensed consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. 3.00% – 2020 Convertible Notes On March 9, 2020, we issued $21.3 million of 3.00% Convertible Notes and elected the fair value option of accounting for this debt instrument (see Note 6, Long Term Debt for details). At June 30, 2021, the contractual outstanding principal of the 3.00% Convertible Notes Due 2025 was $21.3 million and the fair value was $36.2 million. As of June 30, 2021, we measured fair value using a binomial lattice model (which is discussed in further detail below) with the following significant inputs: Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 48.45 % Conversion price discount 25 % We recorded a loss of $1.1 million and $4.1 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with the subsequent fair value remeasurement of the 3.00% Convertible Notes, as follows (in thousands): Fair value at December 31, 2020 $ 32,106 Plus: Loss from change in fair value $ 4,108 Fair value at June 30, 2021 $ 36,214 A binomial lattice model was used to determine the fair value of the 3.00% Convertible Notes Due 2025 based on assumptions as to when these would be converted or redeemed at each decision point. Within the lattice model, the following assumptions were made: (i) upon IPO/Sale/Merger/SPAC or maturity, the convertible notes may be converted to Ordinary Shares or redeemed at principal and accrued interest; and (ii) upon qualified financing event, the convertible notes will automatically convert to Ordinary Shares. The lattice model uses the stock price, conversion price, maturity date, risk-free rate, estimated stock volatility and estimated credit spread. We remeasure the fair value of the debt instrument and record a change as a gain or loss in the statements of operations and comprehensive loss for each reporting period. 8.00% – 2020 Convertible Notes On February 19, 2020, we issued $8.0 million of 8.00% Convertible Notes and elected the fair value option of accounting for this debt instrument (see Note 6, Long Term Debt for details). At June 30, 2021, the contractual outstanding principal of the 8.00% Convertible Notes Due 2027 was $8.0 million and the fair value was $17.0 million (including embedded warrants). As of June 30, 2021, we measured fair value using a binomial lattice model (which is discussed in further detail below) with the following significant inputs: Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 35 % Conversion price discount 40 % We recorded a loss of $0.5 million and $2.2 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with the subsequent fair value remeasurement of the 8.0% Convertible Notes, as follows (in thousands): Fair value at December 31, 2020 $ 14,789 Plus: Loss from change in fair value $ 2,249 Fair value at June 30, 2021 $ 17,038 A binomial lattice model was used to determine the fair value of the 8.00% Convertible Notes Due 2025 based on assumptions as to when these would be converted or redeemed at each decision point. Within the lattice model, the following assumptions were made: (i) upon IPO/Sale/Merger/SPAC or maturity, the convertible notes may be converted to Ordinary Shares or put at 125% of principal and accrued interest; and (ii) upon financing event, the convertible notes may be converted to Ordinary Shares. We remeasure the fair value of the debt instrument and record a change as a gain or loss from in the statements of operations and comprehensive loss for each reporting period. We issued liability classified warrants in conjunction with the issuance of the 8.00% Convertible Notes. The fair value of these warrants is embedded within the fair value of the 8.00% Convertible Notes presented in the table above. 2020 Term Facility Loan On September 29, 2020, we issued $35.0 million of convertible notes and elected the fair value option of accounting for this debt instrument (see Note 6, Long Term Debt for details). At June 30, 2021, the contractual outstanding principal of the 2020 Term Facility Loan was $33.9 million and the fair value was $40.0 million. As of June 30, 2021, we measured fair value using a binomial lattice model and discounted cash flow approach for various exit event scenario, with the following significant inputs: Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 35 % We recorded a loss of $1.2 million and $14.9 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with the subsequent fair value remeasurement of 2020 Term Facility Loan, as follows (in thousands): Fair value at December 31, 2020 $ 25,049 Plus: Loss from change in fair value $ 14,921 Fair value at June 30, 2021 $ 39,970 A binomial lattice model was used to determine the fair value of the 2020 Term Facility Loan based on assumptions as to when these would be converted upon IPO/Sale/Merger/SPAC. Upon such event, the convertible notes will be paid off as following: (i) if par value exit, repayment of base multiple times principal plus unpaid interest; (ii) if greater value exit, repayment of base multiple plus add-on 5.00% – $50.0 Million Convertible Notes On January 11, 2021, we issued $50.0 million of 5.00% – $50.0 Million Convertible Notes and elected the fair value option of accounting for this debt instrument (see Note 6, Long Term Debt for details). At June 30, 2021, the contractual outstanding principal of the 5.00% – $50.0 Million Convertible Notes Due 2026 was $10.3 million and the fair value was $11.2 million. As of June 30, 2021, we measured fair value using a binomial lattice model (which is discussed in further detail below) with the following significant inputs: Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 48.4 % We recorded a loss of $0.3 million and $0.9 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with the subsequent fair value remeasurement of 5.00% – $50.0 Million Convertible Note, as follows (in thousands): Fair value at January 11, 2021 $ 10,274 Plus: Loss from change in fair value $ 946 Fair value at June 30, 2021 $ 11,220 A binomial lattice model was used to determine the fair value of the 5.00% – $50.0 Million Convertible Notes Due 2026 based on assumptions as to when these would be converted or redeemed at each decision point. Within the lattice model, the following assumptions are made: (i) upon IPO/Sale/Merger/SPAC, the convertible notes may be converted to Ordinary Shares or put at principal and accrued interest; and (ii) upon qualified financing event or maturity, the convertible notes will automatically convert to Ordinary Shares at base price. The lattice model uses the stock price, conversion price, maturity date, risk-free rate, estimated stock volatility and estimated credit spread. We remeasure the fair value of the debt instrument and record the change as a gain or loss from a change as a gain or loss in the statements of operations and comprehensive loss for each reporting period. 5.00% – $25.0 Million Convertible Notes On December 31, 2020, we issued $25.0 million of 5.00% – $25.0 Million Convertible Notes and elected the fair value option of accounting for this debt instrument (see Note 6, Long Term Debt for details). At June 30, 2021, the contractual outstanding principal of the 5.00% – $25.0 Million Convertible Notes Due 2025 was $25.0 million and the fair value was $43.1 million (including embedded warrants). As of June 30, 2021, we measured fair value using a binomial lattice model (which is discussed in further detail below) with the following significant inputs: Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 48.4 % We recorded a loss of $1.3 million and $5.5 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with subsequent fair value remeasurement of the 5.00% – $25.0 Million Convertible Notes, as follows (in thousands): Fair value at December 31, 2020 $ 37,592 Plus: Loss from change in fair value $ 5,478 Fair value at June 30, 2021 $ 43,070 A binomial lattice model was used to determine the fair value of the 5.00% – $25.0 Million Convertible Notes Due 2025 based on assumptions as to when these would be converted or redeemed at each decision point. Within the lattice model, the following assumptions were made: (i) upon SPAC, the convertible notes may be converted to Ordinary Shares or put at principal and accrued interest; (ii) upon qualified financing event, the convertible notes may be converted to Ordinary Shares with discount any time after financing date; and (iii) upon maturity, the convertible notes may convert to Ordinary Shares at $675.0 million divided by the number of fully diluted shares. We remeasure the fair value instrument We issued liability classified warrants in conjunction with the issuance of the 5.00% – $25.0 Million Convertible Notes. We evaluated the terms of these warrants and noted that under ASC 480, our potential obligation to settle the warrants only when the exercise of contingencies is met. Due to this provision, ASC 480 requires that the warrants are classified as liabilities and combined within the % – $ Million Convertible Notes. The fair value of these warrants is embedded within the fair value of the % – $ Million Convertible Notes presented in the table above. 5.00% – $30.0 Million Convertible Notes On January 11, 2021, we issued $30.0 million of 5.00% Convertible Notes and elected the fair value option of accounting for this debt instrument (see Note 6, Long Term Debt for details). At June 30, 2021, the contractual outstanding principal of the 5.00% – $30.0 Million Convertible Notes Due 2026 was $30.0 million and the fair value was $46.8 million. As of June 30, 2021 we measured fair value using a binomial lattice model (which is discussed in further detail below) with the following significant inputs:​​​​​​​ Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 48.4 % We recorded a loss of $1.4 million and $8.4 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with the subsequent fair value remeasurement of the 5.00% – $30.0 Million Convertible Notes, as follows (in thousands): Fair value at January 11, 2021 $ 38,403 Plus: Loss from change in fair value $ 8,413 Fair value at June 30, 2021 $ 46,816 A binomial lattice model was used to determine the fair value of the 5.00% Convertible Notes Due 2026 based on assumptions as to when these would be converted or redeemed at each decision point. Within the lattice model, the following assumptions were made: (i) upon SPAC, the convertible notes may be converted to Ordinary Shares or put at principal and accrued interest; and (ii) upon qualified financing event or maturity, the convertible notes will automatically convert to Ordinary Shares at base price. The lattice model uses the stock price, conversion price, maturity date, risk-free rate, estimated stock volatility and estimated credit spread. We remeasure the fair value of the debt instrument and record a change as a gain or loss in the statements of operations and comprehensive loss for each reporting period. At June 30, 2021 and December 31, 2020, the carrying value of certain financial instruments, such as cash, accounts receivable, other receivable, prepaid expenses and other current assets, trade payable and other current accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable.	5. Fair Value Measurements Our financial assets as of December 31, 2020 and 2019 are considered Level 1 in the fair value hierarchy and measured at fair value as follows: December 31, 2020 2019 Assets Money market funds $ 11,516 $ 12,343 All of our financial liabilities as of December 31, 2020, and 2019, are considered Level 3 in the fair value hierarchy, where inputs to the valuation techniques used to measure fair value were considered unobservable. The fair value of our liabilities are as follows (in thousands): December 31, 2020 2019 Liabilities 3.0% – 2020 Convertible Notes $ 32,106 — 8.00% – 2020 Convertible Notes 14,789 — 2020 Term Facility Loan 25,049 — 2017 Term Loan — 1,952 Total financial liabilities $ 71,944 $ 1,952 The fair value of the 2017 Term Loan approximates the carrying value, as of December 31, 2019, due to the rate of interest of the Term Loan being variable. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. At December 31, 2020 and December 31, 2019, the carrying value of certain financial instruments, such as cash equivalents, accounts receivable, other receivable, prepaid expenses and other current assets, trade payable and other current accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. 3.0% – 2020 Convertible Notes On March 9, 2020, we issued $21.3 million of 3.0% Convertible Notes and elected the fair value option of accounting for this debt instrument (see Note 7, Long Term Debt for details). At December 31, 2020, the contractual outstanding principal of the 3.0% Convertible Notes Due 2025 was $21.3 million and the fair value was $32.1 million. As of December 31, 2020, we measured fair value using a binominal lattice model (which is discussed in further detail below) with the following significant inputs: Fair Value per share of Ordinary Shares $20.28 Risk-free interest rate 0.08% - 0.10 % Expected volatility 55 % Expected term, in years 0.14 - 4.19 Discount yield 48.4 % Conversion price discount 25% - 40 % For the year ended December 31, 2020, we recorded a $10.8 million loss from change in fair value of debt in connection with the initial issuance and subsequent fair value remeasurement of the 3.0% Convertible Notes, as follows (in thousands): Fair value at March 9, 2020 $ 21,281 Plus: Loss from change in fair value 10,825 Fair value at December 31, 2020 $ 32,106 A binomial lattice model was used to determine the fair value of the 3.0% Convertible Notes Due 2025 based on assumptions as to when these would be converted or redeemed at each decision point. Within the lattice model, the following assumptions are made: (i) upon IPO/Sale/Merger/SPAC or maturity, the convertible notes may be converted to Ordinary Shares or redeemed at principal and accrued interest; and (ii) upon qualified financing event, the convertible notes will automatically convert to Ordinary Shares. The lattice model uses the stock price, conversion price, maturity date, risk-free rate, estimated stock volatility and estimated credit spread. We remeasure the fair value of the debt instrument and record the change as a gain or loss from change in fair value of debt in the statements of operations and comprehensive loss for each reporting period. 8.00% – 2020 Convertible Notes On February 19, 2020, we issued $8.0 million of 8.0% Convertible Notes and elected the fair value option of accounting for this debt instrument (see Note 7, Long Term Debt for details). At December 31, 2020, the contractual outstanding principal of the 8.0% Convertible Notes Due 2027 was $8.0 million and the fair value was $14.8 million (including embedded warrants). As of December 31, 2020, we measured fair value using a binominal lattice model (which is discussed in further detail below) with the following significant inputs: Fair Value per share of Ordinary Shares $20.28 Risk-free interest rate 0.08% - 0.52 % Expected volatility 55 % Expected term, in years 0.14 - 6.14 Discount yield 35 % Conversion price discount 25% - 40 % For the year ended December 31, 2020, we recorded a $ 4.4 Fair value at February 19, 2020 $ 10,415 Plus: Loss from change in fair value 4,374 Fair value at December 31, 2020 $ 14,789 A binomial lattice model was used to determine the fair value of the 8.0% Convertible Notes Due 2025 based on assumptions as to when these would be converted or redeemed at each decision point. Within the lattice model, the following assumptions are made: (i) upon IPO/Sale/Merger/SPAC or maturity, the convertible notes may be converted to Ordinary Shares or put at 125% of principal and accrued interest; and (ii) upon financing event, the convertible notes may be converted to Ordinary Shares. We remeasure the fair value of the debt instrument and record the change as a gain or loss from change in fair value of debt in the statements of operations and comprehensive loss for each reporting period. We issued liability classified warrants in conjunction with the issuance of the 8.0% Convertible Notes. We evaluated the terms of these warrants and noted that under ASC 480, our potential obligation to settle the warrants only when the exercise of contingencies is met. Due to this provision, ASC 480 requires that these warrants be classified as liabilities and combined within the 8.0% Convertible Notes. The fair value of these warrants is embedded within the fair value of the 8.0% Convertible Notes presented in the table above. 2020 Term Facility Loan On September 29, 2020, we issued $35.0 million of convertible notes and elected the fair value option of accounting for this debt instrument (see Note 7, Long Term Debt for details). At December 31, 2020, the contractual outstanding principal of the 2020 Term Facility Loan was $22.5 million and the fair value was $25.1 million. As of December 31, 2020, we measured fair value using a binominal lattice model and discounted cash flow approach for various exit event scenario, with the following significant inputs: Fair Value per share of Ordinary Shares $20.28 Risk-free interest rate 0.21 % Expected volatility 55 % Expected term, in years 0.14 - 4.13 Discount yield 35 % For the year ended December 31, 2020, we recorded a $1.7 million loss from change in fair value of debt in connection with the initial issuance and subsequent fair value remeasurement of 2020 Term Facility Loan, as follows (in thousands): Fair value at September 29, 2020 $ 23,320 Plus: Loss from change in fair value 1,729 Fair value at December 31, 2020 $ 25,049 A binomial lattice model was used to determine the fair value of the 2020 Term Facility Loan based on assumptions as to when these would be converted upon IPO/Sale/Merger/SPAC. Upon such event, the convertible notes will be paid off as following: (i) if par value exit, repayment of base multiple times principal plus unpaid interest; (ii) if greater value exit, repayment of base multiple plus add-on We used the probability weighted discounted cash flow approach to determine if the 2020 Term Facility Loan would be converted upon qualified financing or maturity. Upon the qualified financing, the convertible notes will not be converted and will remain outstanding until maturity and put at 280% principal plus unpaid interest. Upon maturity, the convertible notes will be repaid at a full principal balance. We remeasure the fair value of the debt instrument and record the change as a gain or loss from change in fair value of debt in the statements of operations and comprehensive loss for each reporting period. 2019 Convertible Notes During 2019, we issued convertible loan notes in an aggregate principal amount of $15.0 million (see Note 7, “Long Term Debt” for details). We elected to account for the 2019 Convertible Notes at fair value. Management believes that the fair value option better reflects the underlying economics of the 2019 Convertible Notes, which contains embedded derivatives. The notes were converted to Ordinary Shares due to a qualified financing event in June 2019. During 2019, the 2019 Convertible Notes were

Balance Sheet Components

Balance Sheet Components	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	5. Balance Sheet Components Cash and cash equivalents Cash and cash equivalents balances were concentrated by location as follows: As of June 30, December 31, (Unaudited) United Kingdom 92 % 96 % United States 7 % 3 % Other 1 % 1 % Other receivables (in thousands As of June 30, December 31, (Unaudited) R&D tax credit receivable $ 21,911 $ 17,412 Grants receivable 573 — VAT receivable 549 607 Other receivable 4 5 Total other receivables $ 23,037 $ 18,024 Property and equipment, net (in thousands): As of June 30, December 31, (Unaudited) Computer equipment $ 1,744 $ 1,218 Lab equipment 10,081 7,607 Motor vehicles 31 31 Furniture and fixtures 265 265 Leasehold improvements 704 704 Assets under construction 561 27 Total property and equipment $ 13,386 $ 9,852 Less: accumulated depreciation (7,162 ) (5,802 ) Total property and equipment, net $ 6,224 $ 4,050 Total depreciation expense for the three months ended June 30, 2021 and 2020 was $1.0 million and $0.6 million, respectively. Total depreciation expense for the six months ended June 30, 2021 and 2020 was $1.8 million and $1.2 million, respectively. Finance lease right-of-use net As of June 30, December 31, (Unaudited) Finance lease right-of-use $ 2,966 $ 2,966 Less: accumulated amortization (1,020 ) (834 ) Total finance lease right-of-use assets, net $ 1,946 $ 2,132 Amortization expense for the three months ended June 30, 2021 and 2020 was $0.1 million and $0.1 million, respectively. Amortization expense for the six months ended June 30, 2021 and 2020 was $0.2 million and $0.2 million, respectively. Intangible assets, net (in thousands): As of June 30, December 31, (Unaudited) In-process $ 3,048 $ 3,048 Total intangible assets, net $ 3,048 $ 3,048 The Company reviews its intangible assets for potential impairment whenever events or circumstances indicate that the carrying value of the intangible assets may not be recoverable. No impairment charges were recorded for the three and six months ended June 30, 2021 and 2020. Other non-current As of June 30, December 31, (Unaudited) Capitalized transaction costs $ 8,496 $ 121 Operating right of use assets 3,219 1,486 Total other non-current $ 11,715 $ 1,607 Capitalized transaction costs as of June 30, 2021 consist of capitalized professional fees related to accounting, legal and audit matters incurred by the Company, in connection with the Business Combination transaction. Accrued expenses (in thousands): As of June 30, December 31, (Unaudited) Accrued bonus $ 2,926 $ 3,349 Accrued payroll and benefits 2,191 1,524 Accrued taxes 75 332 Accrued fabrication costs 2,304 2,321 Share appreciation rights 741 706 Other accrued expenses 3,867 2,163 Total accrued expenses $ 12,104 $ 10,395	6. Balance Sheet Components Cash and cash equivalents Our cash and cash equivalents balances as of December 31, 2020 and 2019 were concentrated by location as follows: December 31, 2020 2019 United Kingdom 96 % 95 % United States 3 % 4 % Other 1 % 1 % We have not experienced any losses on cash and cash equivalents to date. Other receivables Other receivables consist of the following (in thousands): As of December 31, 2020 2019 R&D tax credit receivable $ 17,412 $ 14,731 Grants receivable — 239 VAT receivable 607 886 Other receivable 5 93 Total other receivables $ 18,024 $ 15,949 The research and development tax credit receivable consists of research and development expenses that have been claimed as research and development tax credits in accordance with the relevant U.K. tax legislation. These refundable tax credits are payable to the Company in cash and are carried on the consolidated balance sheet at the amount claimed and expected to be received from the U.K. government within the next 12 months. The amount of the R&D tax credit has been recorded as a reduction to cost of revenue and operating expenses (based on the nature of the underlying expenditure) on the accompanying consolidated statements of operations and comprehensive loss. Property, equipment and finance lease right-of-use Property and equipment, net consisted of the following (in thousands): As of December 31, 2020 2019 Computer equipment $ 1,218 $ 1,020 Lab equipment 7,607 5,614 Motor vehicles 31 31 Furnitures and fixtures 265 265 Leasehold improvements 704 704 Assets under construction 27 587 Total property and equipment $ 9,852 $ 8,221 Less: accumulated depreciation (5,802 ) (3,561 ) Total property and equipment, net $ 4,050 $ 4,660 Depreciation expense was $2.4 million and $1.5 million for the years ended December 31, 2020, and 2019, respectively. Finance lease right-of-use As of December 31, 2020 2019 Finance lease right-of-use $ 2,966 $ 3,105 Less: accumulated amortization (834 ) (485 ) Total finance lease right-of-use assets, net $ 2,132 $ 2,620 Amortization expense was $0.4 million and $0.4 million for the years ended December 31, 2020, and 2019, respectively. Intangible asset Intangible asset consisted of the following (in thousands): As of 2020 2019 In-process $ 3,048 $ — Total intangible asset $ 3,048 $ — Accrued expenses Accrued expenses consist of the following (in thousands): As of 2020 2019 Accrued bonus $ 3,349 $ 2,501 Accrued payroll and benefits 1,524 602 Accrued taxes 332 75 Accrued fabrication costs 2,321 1,884 Share appreciation rights 706 435 Other accrued expenses 2,163 1,355 Total accrued expenses $ 10,395 $ 6,852

Long Term Debt

Long Term Debt	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Long Term Debt	6. Long Term Debt The following table summarizes information June 30, 2021 (Unaudited) Principal Fair Value Net 3.00% – 2020 Convertible Notes $ 21,281 $ 14,933 $ 36,214 8.00% – 2020 Convertible Notes 8,000 9,038 17,038 2020 Term Facility Loan 33,949 6,021 39,970 5.00% – $50.0 Million Convertible Notes 10,274 946 11,220 5.00% – $25.0 Million Convertible Notes 25,000 18,070 43,070 5.00% – $30.0 Million Convertible Notes 30,000 16,816 46,816 Total long-term debt $ 128,504 $ 65,824 $ 194,328 Less: current portion of long-term debt — — — Long-term debt, net of current portion $ 128,504 $ 65,824 $ 194,328 December 31, 2020 Principal Fair Value Net 3.00% – 2020 Convertible Notes $ 21,281 $ 10,825 $ 32,106 8.00% – 2020 Convertible Notes 8,000 6,789 14,789 2020 Term Facility Loan 22,500 2,549 25,049 Paycheck Protection Program 2,860 — 2,860 Total long-term debt $ 54,641 $ 20,163 $ 74,804 Less: current portion of long-term debt — — — Long-term debt, net of current portion $ 54,641 $ 20,163 $ 74,804 Future minimum payments under the debt agreements as of June 30, 2021 are as follows (in thousands): Convertible Notes 2021 (for the remaining period) $ — 2022 — 2023 — 2024 — 2025 114,179 Thereafter 50,274 Total future minimum payments $ 164,453 Less: current portion of debt principal — Non-current $ 164,453 3.00% – 2020 Convertible Notes The discussion on the 3.00% – 2020 Convertible Notes is fully described in Note 7 of the “Notes to Consolidated Financial Statements” included in the Rockley Photonics Holdings Limited’s Registration Statement on Form S-4 No. 333-255019), We accrued unpaid interest of $0.1 million and $0.3 million in the three and six months ended June 30, 2021, respectively. The accrued unpaid interest for the three and six months ended June 30, 2020 was immaterial. For the three and six months ended June 30, 2021, we recorded a loss of $1.1 million and $4.1 million, respectively in the condensed consolidated statements of operations and comprehensive 8.00% – 2020 Convertible Notes The discussion on the 8.00% Convertible Notes is fully described in Note 7 of the “Notes to Consolidated Financial Statements” included in the Rockley Photonics Holdings Limited’s Registration Statement on Form S-4 No. 333-255019), We accrued unpaid interest of $0.2 million and $0.3 million in the three and six months ended June 30, 2021, respectively. We accrued unpaid interest of $0.1 million and $0.2 million for the three and six months ended June 30, 2020, respectively. For the three and six months ended June 30, 2021, we recorded a loss of $0.5 million and $2.2 million, respectively in the condensed consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. See Note 4, Fair Value Measurements for information about the assumptions used to measure the fair value of 8.00% Convertible Notes as of June 30, 2021. 2020 Term Facility Loan The discussion on the 2020 Term Facility Loan is fully described in Note 7 of the “Notes to Consolidated Financial Statements” included in the Rockley Photonics Holdings Limited’s Registration Statement on Form S-4 No. 333-255019), The Company paid interest of $0.2 million and $0.3 million in the three and six months ended June 30, 2021, respectively. As of June 30, 2021, the total amount borrowed was $33.9 million. For the three and six months ended June 30, 2021, we recorded a loss of $1.2 million and $14.9 million, respectively in the condensed consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. See Note 4, Fair Value Measurements for information about the assumptions used to measure the fair value of 2020 Term Facility Loan as of June 30, 2021. On May 25, 2021, we entered into an amendment to the 2020 Term Facility Loan which modified the payment and maturity terms such that 30 5.00% – $50.0 Million Convertible Notes On January 11, 2021, we issued convertible loan notes for an aggregate principal amount of $50.0 million. The 5.00% – $50.0 Million Convertible Notes mature on the fifth anniversary date of the instrument and bear interest at a rate of 5.0% per annum. The 5.00% – $50.0 Million Convertible Notes contain no financial covenants. We accrued unpaid interest of $0.1 million and $0.3 million in the three and six months ended June 30, 2021, respectively. As of June 30, 2021, the total amount borrowed was $10.3 million. The 5.00% – $50.0 Million Convertible Notes are convertible as follows: (a) In the event of a qualified financing even with total proceeds raised not less than $25.0 million, the outstanding principal amount and any unpaid accrued interest shall automatically convert into the most senior class of share at a conversion price being lower of 15% discount to the per share subscription price of the equity shares or the price obtained by diving $1,500.0 million by fully diluted share capital of the Company at the date of conversion; (b) At an exit event, redeem the outstanding principal amount and any unpaid accrued interest on the original principal or convert the outstanding principal amount of all notes and any unpaid accrued interest into the most senior class of share of the Company at a conversion price equal to the lower of 15% discount to the price per share and the price obtained by dividing $1,500.0 million by fully diluted share capital of the Company at the date of conversion; (c) At the maturity date, convert into the most senior class of shares at a conversion price by dividing $1,500.0 million by fully diluted share capital of the Company at the date of conversion. We elected to account for the 5.00% – $50.0 Million Convertible Notes at fair value as of the issuance date. Management believes that the fair value option better reflects the underlying economics of the 5.0% – $50.0 Million Convertible Notes. Under the fair value election, changes in fair value are reported in the condensed consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. For the three and six months ended June 30, 2021, we recorded a loss of $0.3 million and $0.9 million, respectively. See Note 4, Fair Value Measurements for information about the assumptions we used to measure the fair value of the 5.00% – $50.0 Million Convertible Notes. 5.00% – $25.0 Million Convertible Notes On December 31, 2020, we issued convertible loan notes in an aggregate principal amount of $25.0 million. The 5.00% – $25.0 Million Convertible Notes mature on the fifth anniversary date of the instrument and bear interest at a rate of 5.0% per annum. The 5.00% – $25.0 Million Convertible Notes contain no financial covenants. We accrued unpaid interest of $0.3 million and $0.6 million in the three and six months ended June 30, 2021. The 5.00% – $25.0 Million Convertible Notes were convertible as follows: (a) In an equity qualified financing event with total proceeds raised not less than $25.0 million, the outstanding principal amount and any unpaid accrued interest shall automatically convert into the most senior class of share at a conversion price being lower of 25% discount to the per share subscription price (b) At an exit event, redeem the outstanding notes for an amount equal to 100% of the outstanding principal plus accrued interest or convert the outstanding principal amount into the most senior class of share of the Company, at a conversion price equal to the lower of 25% discount to the price per share and the price obtained by dividing $800.0 million by fully diluted share capital of the Company at the date of conversion; or (c) At the maturity date, convert into the most senior class of shares at a conversion price by dividing $675.0 million by the number of issued shares in the capital of the Company on a fully diluted basis or repay the amount equal to 100% of the outstanding principal amount plus any accrued interest. We elected to account for the 5.00% – $25.0 Million Convertible Notes at fair value as of the issuance date. Management believes that the fair value option better reflects the underlying economics of the 5.00% – $25.0 Million Convertible Notes. Under the fair value election, changes in fair value are reported in the condensed consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. For the three and six months ended June 30, 2021, we recorded a loss of $1.3 million and $5.5 million, respectively. See Note 4, Fair Value Measurements In conjunction with the 5.00% – $25.0 Million Convertible Notes, we also issued the holder 278,775 warrants (“5.0% Investor Warrants”) which are convertible into Ordinary Shares of the Company. The warrants have an exercise price of $0.00001 per share and will only become exercisable upon the specified conversion event. The number of shares that the warrants will convert into varies depending on the type of conversion event. The value of the warrants is embedded within the 5.00% – $25.0 Million Convertible Notes. 5.00% – $30.0 Million Convertible Notes On January 11, 2021, we issued convertible loan notes in an aggregate principal amount of $30.0 million (the “5.00% – $30.0 Million Convertible Notes”). The 5.00% – $30.0 Million Convertible Notes mature on the fifth anniversary date of the instrument and bear interest at a rate of 5.0% per annum. The 5.00% – $30.0 Million Convertible Notes contain no financial covenants. We accrued unpaid interest of $0.4 million and $0.7 million in the three and six months ended June 30, 2021, respectively. The 5.00% – $30.0 Million Convertible Notes were convertible as follows: (a) In an equity qualified financing event with total proceeds raised not less than $25.0 million, the outstanding principal amount and any unpaid accrued interest shall automatically convert into the most senior class of share at a conversion price being lower of 25% discount to the per share subscription price of the equity shares or the price obtained by diving $800.0 million by fully diluted share capital of the Company at the date of conversion; (b) At an exit event, redeem the outstanding notes for an amount equal to the outstanding principal plus any unpaid accrued interest or convert the outstanding principal amount of all notes and any unpaid accrued interest into the most senior class of share of the Company, at a conversion price equal to the lower of a 25% discount to the price per share and the price obtained by dividing $800.0 million by fully diluted share capital of the Company at the date of conversion; or (c) At the maturity date, convert into the most senior class of shares at a conversion price by dividing $800.0 million by fully diluted share capital of the Company at the date of conversion. We elected to account for the 5.00% – $30.0 Million Convertible Notes at fair value as of the issuance date. Management believes that the fair value option better reflects the underlying economics of the 5.00% – $30.0 Million Convertible Notes. Under the fair value election, changes in fair value are reported in the condensed consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. For the three and six months ended June 30, 2021, we recorded a loss of $1.4 million and $8.4 million, respective. See Note 4, Fair Value Measurements for information about the assumptions we used to measure the fair value Paycheck Protection Program The discussion on paycheck protection program is fully described in Note 7 of the “Notes to Consolidated Financial Statements” included in the Rockley Photonics Holdings Limited’s Registration Statement on Form S-4 No. 333-255019), During June 2021, the $2.9 million of borrowings outstanding under the Paycheck Protection Program (“PPP”) Loan was forgiven in full. Forgiveness income is recorded as a component of other income, net in the condensed consolidated statements of operations and comprehensive loss .	7. Long Term Debt The following table summarizes information relating to our long-term debt, (in thousands): December 31, 2020 Principal Fair Value Net 3.0% – 2020 Convertible Notes $ 21,281 $ 10,825 $ 32,106 8.00% – 2020 Convertible Notes 8,000 6,789 14,789 2020 Term Facility Loan 22,500 2,549 25,049 Paycheck Protection Program 2,860 — 2,860 Total long-term debt $ 54,641 $ 20,163 $ 74,804 Less: current portion of long-term debt — — — Long-term debt, net of current portion $ 54,641 $ 20,163 $ 74,804 Future minimum payments under the debt agreements as of December 31, 2020 are as follows (in thousands): Convertible Year Ending December 31: 2021 $ — 2022 — 2023 — 2024 — 2025 66,281 Thereafter 10,000 Total future minimum payments $ 76,281 Less: current portion of debt principal — Non-current $ 76,281 January 2017 Term Loan and May 2017 Term Loan On January 27, 2017, we secured a term loan of $5.0 million from Silicon Valley Bank (“January 2017 Term Loan”). The January 2017 Term Loan matured on March 31, 2020, with an interest only period through March 31, 2017 preceding the 36-month On May 26, 2017, we secured a new term loan for $10.0 million of which $5.0 million was provided by Silicon Valley Bank and €4.5 million was provided by Kreos Capital (“May 2017 Term Loan”). The May 2017 Term Loan had a thirty The $5.0 million received from Silicon Valley Bank under the May 2017 Term Loan was used to repay the January 2017 Term Loan and we received a waiver of the prepayment fee. The repayment of the January 2017 Term Loan was treated as a modification of debt. Therefore, additional fees paid to the creditor was reflected as additional debt discount and amortized over the remaining term using the interest method and has been fully amortized as of December 31, 2020 and was immaterial as of December 31, 2019. Under the January 2017 Term Loan, Silicon Valley Bank and under the May 2017 Term Loan, Kreos Capital each received 52,050 warrants to purchase Ordinary Shares of the Company at an exercise price of $8.646 per warrant (“Bank Warrants”). The Silicon Valley Bank and Kreos Capital warrants expire on January 27, 2027 and May 26, 2027, respectively. See Note 11 for further discussion regarding warrants. 2019 Convertible Notes During 2019, we issued convertible loan notes in an aggregate principal amount of $15.0 million (“2019 Convertible Notes”). The 2019 Convertible Notes mature on the second (a) if in an equity financing raised total proceeds for the Company of not less than $10.0 million then the outstanding principal amount of all notes and any unpaid accrued interest shall automatically convert into the most senior class of share at a conversion price of $11.4384, equal to a 20% discount to the Series E issuance price of $14.298 per share; or (b) At an exit event, convert the outstanding principal amount of all notes and any unpaid accrued interest thereon into the most senior class of share of the Company, at a conversion price equal to the Series E issuance price of $14.298 per share. (c) At the maturity date, convert into the most senior class of share at a conversion price equal to the Series E issuance price of $14.298. We elected to account for the 2019 Convertible Notes at fair value as of the issuance date. Management believes that the fair value option better reflects the underlying economics of the 2019 Convertible Notes, which contains embedded derivatives. Under the fair value election, changes in fair value are reported in the consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. On June 12, 2019, we received equity financing of $24.0 million, resulting in the automatic conversion of the 2019 Convertible Notes. Upon settlement, we recorded interest expense in the amount of $0.3 million for the amount that would have been accrued from the issuance date to the settlement date at annual rate of 8%, on the $15.0 million of principal under the terms of the 2019 Convertible Notes. To extinguish the 2019 Convertible Notes, 1,336,344 Ordinary Shares were issued. A loss of $3.0 million was generated on the extinguishment of the liability during the conversion based on the difference between the fair value of the shares at $13.65 and the conversion price of $11.44 and was recorded in statements of operations and comprehensive loss under change in fair value of debt instruments. 3.0% – 2020 Convertible Notes On March 9, 2020, we issued convertible loan notes in an aggregate principal amount of $21.3 million (the “3.0% Convertible Notes”). The 3.0% Convertible Notes mature on the fifth and bear interest at a rate of 3.0% per annum. The 3.0% Convertible Notes contain no financial covenants. We accrued but unpaid interest of $0.3 million for the year ended December 31, 2020. The 3.0% Convertible Notes were issued in two tranches – $20.0 million on March 9, 2020 and $1.3 million on October 20, 2020. The 3.0% Convertible Notes were convertible as follows: (a) If in an equity financing raised total proceeds for the Company of not less than $10.0 million then the outstanding principal amount of all notes and any unpaid accrued interest shall automatically convert into the most senior class of equity share at a conversion price of $14.298 per share; or (b) if an equity financing is not raised for the Company, then the outstanding principal amount of all notes and any unpaid accrued interest may convert into the most senior class of share at a conversion price of $14.298 per share. (c) At an exit event, redeem the outstanding notes for an amount equal to the outstanding principal plus accrued interests or convert the outstanding principal amount of all notes and any unpaid accrued interest thereon into the most senior class of share of the Company, at a conversion price equal to the issuance price of $14.298 per share. (d) At the maturity date, convert into the most senior class of shares at a conversion price equal to the issuance price of $14.298 per share. We elected to account for the 3.0% Convertible Notes at fair value as of the issuance date. Management believes that the fair value option better reflects the underlying economics of the 3.0% Convertible Notes. Under the fair value election, changes in fair value are reported in the consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. For the year ended December 31, 2020, we recorded a loss of $10.8 million which is shown as Fair Value Adjustment in the table at the beginning of this Note 7. See Note 5, Fair Value Measurements for information about the assumptions we used to measure the fair value of the 3.0% Convertible Notes. 8.00% – 2020 Convertible Notes On February 19, 2020, we issued convertible loan notes to our board member in an aggregate principal amount of $8.0 million (the “8.0% Convertible Notes”). The 8.0% Convertible Notes mature on the seventh (a) In the event of an equity financing, the outstanding principal amount of all notes and any unpaid accrued interest shall automatically convert into the most senior class of share at a conversion price being the lower of 14.298 per share or a discounted subscription price of the equity shares; or (b) At an exit event, convert the outstanding principal amount of all notes and any unpaid accrued interest thereon into the most senior class of share of the Company, at a conversion price, equal to a 25% discount to the Series E issuance price of $14.298 per share. (c) At the maturity date, convert into the most senior class of equity share at a conversion price of $14.298. We elected to account for the 8.0% Convertible Notes at fair value as of the issuance date. Management believes that the fair value option better reflects the underlying economics of the 8.0% Convertible Notes. Under the fair value election, changes in fair value are reported in the consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. For the year ended December 31, 2020, we recorded a loss of $6.8 million which is shown as Fair Value Adjustment in the table at the beginning of this Note 7. See Note 5, Fair Value Measurements for information about the assumptions we used to measure the fair value of 8.0% Convertible Notes. In conjunction with the 8.0% Convertible Notes, we also issued the holder warrants (“Investor Warrants”) which are convertible into Ordinary Shares of the Company. The warrants have an exercise price of $0.00001 per share and will only become exercisable if we fail to achieve certain revenue and contribution margin targets in 2021 and 2022. The number of shares that the warrants will convert into varies according to the proportion of the revenue and contribution targets ultimately achieved. The value of the warrants is embedded within the 8.0% Convertible Notes. 2020 Term Facility Loan On September 29, 2020, we secured a term facility loan of $35.0 million from Argentum (“2020 Term Facility Loan”). The 2020 Term Facility Loan matures on March 29, 2025 and bears interest at a rate of 2.0% per annum. The 2020 Term Facility Loan has no financial covenants. We may extend the maturity date through the filing of an extension request up to an additional one year. The 2020 Term Facility Loan may be voluntarily prepaid in full (no partial repayments), plus the applicable repayment premium payable. The Company paid interest of $0.1 million for the year ended December 31, 2020. The Company shall repay the aggregate amount of the loans utilized in full on the maturity date, subject to no Qualified Exit occurring at the time plus the applicable repayment premium payable. The Qualified Exit means: 1) qualified listing—a flotation or a public offering, the value of which is equal to or exceeds the free float value of $350.0 million; 2) non-qualified Upon any occurrence of a non-qualified We elected to account for the 2020 Term Facility Loan at fair value as of the issuance date. Management believes that the fair value option better reflects the underlying economics of the 2020 Term Facility Loan. Under the fair value election, changes in fair value are reported in the consolidated statements of operations and comprehensive loss under Change in Fair Value of Debt Instruments. For the year ended December 31, 2020, we recorded a loss of $2.5 million which is shown as Fair Value Adjustment in the table at the beginning of this Note 7. See Note 5, Fair Value Measurements for information about the assumptions we used to measure the fair value of 2020 Term Facility Loan. Paycheck Protection Program On April 21, 2020, we received loan proceeds of approximately $2.9 million (“PPP Loan”) under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business. The PPP Loan and accrued interest are forgivable after twenty-four weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The PPP Loan is evidenced by a promissory note, dated as of April 21, 2020 (the “Note”), between the Company, as Borrower, and Silicon Valley Bank, as Lender (the “Lender”). The interest rate on the Note is 1.0% per annum, with interest accruing on the unpaid principal balance computed on the basis of the actual number of days elapsed in a year of 360 days. No payments of principal or interest are due during the six-month Beginning one month following expiration of the Deferral Period and continuing monthly until 24 months from the date of the Note (the “Maturity Date”), we are obligated to make monthly payments of principal and interest to the Lender with respect to any unforgiven portion of the Note, in such equal amounts required to fully amortize the principal amount outstanding on the Note as of the last day of the Deferral Period by the Maturity Date. We are permitted to prepay the Note at any time without payment of any premium. As of December 31, 2020, we had $2.9 million of borrowings outstanding under the PPP Loan, recorded under long term debt in the consolidated statements of operations and comprehensive loss

Income Taxes

Income Taxes	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]
Income Taxes	7. Income Income tax expense was $0.1 million in both the three months ended	8. Income Taxes For the years ended December 31, 2020 and 2019, loss before income taxes were as follows (in thousands): Years Ended December 31, 2020 2019 U.K. Operations $ (82,705 ) $ (53,291 ) Foreign operations 2,997 2,752 Loss before income taxes $ (79,708 ) $ (50,539 ) The components of provision for income tax for the years ended December 31, 2020 and 2019 are as follows (in thousands): Current Deferred Total Year ended December 31, 2020 U.K. operations $ — $ — $ — Foreign jurisdictions 569 — 569 $ 569 $ — $ 569 Current Deferred Total Year ended December 31, 2019 U.K. operations $ — $ — $ — Foreign jurisdictions 311 — 311 $ 311 $ — $ 311 The effective tax rate of the Company’s provision for income taxes differs from the 19% statutory rate of the Company’s U.K. headquarters entity (in thousands, except percentages): Years Ended December 31, 2020 2019 U.K. Statutory Rate $ (15,145 ) 19.0 % $ (9,602 ) 19.0 % Foreign income tax 308 (0.4 )% 96 (0.2 )% Research & Development credit (628 ) 0.8 % (1,086 ) 2.1 % Stock-based compensation 1,293 (1.6 )% 758 (1.5 )% Permanent differences 3,325 (4.2 )% (681 ) 1.3 % Change in valuation allowance 7,480 (9.4 )% 2,636 (5.2 )% Losses not benefited 3,999 (5.0 )% 8,169 (16.1 )% Others, net (63 ) 0.1 % 21 — % Total $ 569 (0.7 )% $ 311 (0.6 )% Deferred Tax Assets and Liabilities Deferred income taxes reflect the net effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. We record income tax expense for the anticipated tax consequences of the reported results of operations using the asset and liability method. Under this method, the Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. The Company records valuation allowances to reduce its deferred tax assets to the net amount that it believes is more likely than not to be realized. Its assessment considers the realization of deferred tax assets on a jurisdictional basis. The significant components of the Company’s deferred taxes are as follows (in thousands): December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 15,066 $ 7,494 Research and development credits — 1,217 Stock-based compensation 1,476 1,057 Lease liabilities 482 916 Accrued liabilities 788 633 Other 2 — Total gross deferred tax assets 17,814 11,317 Less valuation allowance (16,377 ) (9,520 ) Net deferred tax assets $ 1,437 $ 1,797 Deferred tax liabilities: Right-of-use $ (821 ) $ (1,064 ) Property and equipment, principally due to differences in depreciation (592 ) (733 ) Other (24 ) — Total gross deferred tax liabilities (1,437 ) (1,797 ) Net deferred tax assets $ — $ — ASC 740 requires that the tax benefit of net operating losses (“NOLs”), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of our future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. The changes in valuation allowance related to operating activity was an increase in the amount of $6.9 million and $2.8 million during the years ended December 31, 2020 and 2019, respectively. NOLs and tax credit gross carryforwards as of December 31, 2020 are as follows (in thousands): Amount Expiration Years NOLs, U.K. (gross) $ 79,293 See notes below Tax credits, Federal $ — See notes below Tax credits, State $ — See notes below Net Operating Losses As of December 31, 2020, the Company has U.K. NOL of approximately $79.3 million that can be carried forward indefinitely. The U.S. R&D tax credit for the year ended December 31, 2020 has been fully utilized. Uncertain Tax Positions The Company recognizes tax benefits from uncertain tax positions only if it believes that it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. As the Company expands, it will face increased complexity in determining the appropriate tax jurisdictions for revenue and expense items. The Company’s policy is to adjust these reserves when facts and circumstances change. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the income tax expense in the period in which such determination is made and could have a material impact on its financial condition and operating results. The income tax expense includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties. As of December 31, 2020 and 2019, the Company had total uncertain tax positions of $2.2 million and $0.4 million. No interest or penalties have been recorded related to the uncertain tax positions. None of the unrecognized tax benefits, if recognized, would affect the effective tax rate. A reconciliation of the beginning and ending balances of unrecognized tax benefits is as follows (in thousands): Years Ended December 31, 2020 2019 Balance at beginning of the year $ 405 $ 271 Increases based on tax positions related to current year 733 134 Increases based on tax positions related to prior years 1,199 — Decreases based on tax positions related to prior years (101 ) — Balance at end of year $ 2,236 $ 405 It is not expected that there will be a significant change in uncertain tax position in the next 12 months. We are subject to income tax in the U.K., U.S. federal and various states and three other foreign jurisdictions. Our U.S. income tax filings are currently under audit for the tax year ended December 31, 2018. The statute of limitations for U.K. and foreign tax jurisdictions other than the U.S. are no longer subject to audit for tax years before December 31, 2018. We are no longer subject to U.S. federal income tax audit for the tax years before the year ended December 31, 2017 and are no longer subject to state income tax audit for tax years before December 31, 2016.

Ordinary Shares

Ordinary Shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Ordinary Shares	8. Ordinary Shares Ordinary non-cumulative	9. Ordinary Shares Ordinary Shares have no liquidation preferences and entitle holders to one vote per share. Ordinary shareholders are entitled to receive non-cumulative
Rockley Photonics Holdings Limited
Ordinary Shares	2. Shareholder’s Equity On March 11, 2021, upon formation of HoldCo, our board of directors (the Rockley Photonics Holdings Limited Board) authorized the issuance of 1 ordinary share with an initial par value of $0.00001 per share, to Dr. Andrew Rickman, OBE. Rockley contributed additional paid-in

Earnings per Share

Earnings per Share	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share	9. Earnings per Share The following is a calculation of basic and diluted net loss per share (in thousands, except for share and per share amounts): Three Months Ended June 30 Six Months Ended June 30, 2021 2020 2021 2020 (Unaudited) (Unaudited) Basic and diluted Net loss $ (30,557 ) $ (10,003 ) $ (95,334 ) $ (26,429 ) Weighted average Ordinary Shares outstanding 33,922,973 33,625,899 33,850,070 33,554,441 Basic and diluted net loss per share $ (0.90 ) $ (0.30 ) $ (2.82 ) $ (0.79 ) Basic net loss per share is calculated by dividing net loss for the period by the weighted average number of the Ordinary Shares outstanding plus 108,821 and 132,099 outstanding warrants for the three months ended June 30, 2021 and 2020 with a $0.01 exercise price. For the three and six months ended June 30, 2021 and 2020, we excluded the potential effect of the following in the calculation of the diluted loss per share, as the effect would be anti-dilutive due to losses incurred: Three Months Ended Six Months Ended 2021 2020 2021 2020 (Unaudited) (Unaudited) Outstanding warrants, less outstanding warrants with a $0.01 exercise price $ 899,698 $ 842,717 $ 899,698 $ 842,717 Outstanding options (including performance options) $ 6,700,277 $ 6,412,668 $ 6,700,277 $ 6,412,668 $ 7,599,975 $ 7,255,385 $ 7,599,975 $ 7,255,385	10. Earnings Per Share A reconciliation of net loss available to ordinary shareholders and the number of shares in the calculation of basic and diluted net loss per share follows (in thousands, except for share and per share data): Years Ended December 31, 2020 2019 Basic and diluted: Net loss $ (80,277 ) $ (50,850 ) Weighted average Ordinary Shares outstanding 33,604,752 31,406,127 Basic and diluted net loss per share $ (2.39 ) $ (1.62 ) Basic net loss per share is calculated by dividing net loss for the period by the weighted average number of the Ordinary Shares outstanding plus 132,099 outstanding warrants outstanding with a $0.01 exercise price during the period. As of December 31, 2020 and 2019, we excluded the potential effect of the following in the calculation of the diluted loss per share, as the effect would be anti-dilutive due to losses incurred. As of December 31, 2020 2019 Outstanding warrants, less 132,099 outstanding warrants with a $0.01 exercise price 881,004 848,240 Outstanding options 7,207,044 5,904,413 Outstanding performance awards 249,605 249,605 8,337,653 7,002,258

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	10. Stock-Based Compensation The Company has established a number of share-based incentive plans for current employees, directors and others, which include Share Appreciation Rights (“SARs”), 2013 Share Option Plan and Warrants. Share Appreciation Rights As of June 30, 2021 and December 31, 2020, the Company had recorded liabilities of $0.7 million and $0.7 million related to these SARs based on their fair value of $24.70 and $20.28 per share as of June 30, 2021 and December 31, 2020, respectively. The total expense that we recognized for the SARs in the condensed consolidated statements of operations and comprehensive loss under selling, general and administrative was immaterial for the three and six months ended June 30, 2021 and 2020, respectively. 2013 Share Option Plan As of June 30, 2021, there were 11,458,989 shares authorized for issuance under the Plan, of which 3,088,276 shares were available for grant. The following table summarizes the stock option activity related to the 2013 Share Option Plan: Number of Average Remaining Intrinsic (In thousands) Balances as of December 31, 2020 7,207,044 $ 4.94 6.75 $ 110,552 Options granted — $ — Options exercised (164,580 ) $ 1.72 Options forfeited (331,068 ) $ 10.30 Options expired (11,119 ) $ 6.66 Balances as of June 30, 2021 6,700,277 $ 4.75 6.16 $ 133,661 Options exercisable – June 30, 2021 $ 4,989,774 $ 3.56 5.31 $ 105,483 The aggregated intrinsic value represents the difference between the exercise price and the fair value of Ordinary Shares. The weighted-average grant-date fair value of options granted during the six months ended June 30, 2021 was nil since no options were granted during the period. Stock-based compensation expense for all equity arrangements is included in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 (Unaudited) (Unaudited) Cost of revenue $ 363 $ 870 $ 631 $ 1,341 Research and development 1,171 1,330 2,219 2,081 Selling, general and administrative 442 345 851 767 Total stock-based compensation expense $ 1,976 $ 2,545 $ 3,701 $ 4,189 As of June 30, 2021, total unrecognized compensation expense related to unvested options granted to employees under the Company’s stock option plan was $11.9 million, which is expected to be recognized over a weighted average period of 1.2 years. Performance Options For the three months ended June 30, 2021 and 2020, we recognized a total expense of $0.1 million and $0.02 million in relation to the performance-based options. For the six months ended June 30, 2021 and 2020, we recognized a total expense of $0.2 million and $0.1 million. As of June 30, 2021 and December 31, 2020, there were approximately $1.0 million and $1.2 million of unrecognized stock-based compensation expense related to the performance-based options. During the six months ended June 30, 2021, no additional performance-based options were granted. Warrants The following table summarizes information related to our outstanding warrants. Investor Warrants in connection with the 8.00% – 2020 Convertible Notes and 5.00% – $25.0 Million Convertible Notes were excluded from the below table as they are classified as liabilities. Number of Weighted Weighted Balances as of December 31, 2020 1,013,103 $ 7.33 6.45 Warrants issued 18,694 $ 18.16 Warrants exercised (23,278 ) $ 0.00 Balances as of June 30, 2021 1,008,519 $ 7.70 5.78	11. Stock-Based Compensation The Company has established a number of share-based incentive plans for current employees, directors and others, which include Share Appreciation Rights, 2013 Share Option Plan and Warrants. Share Appreciation Rights On November 12, 2013, the Company issued to certain employees Share Appreciation Rights (“SARs”) that require us to pay the intrinsic value of the SARs to the employee at the date of exercise. These SARs vest over a period of four years, provided the employee remains in the employment of the Company and recorded as liabilities at fair value as of the respective period end. As of December 31, 2020 and 2019, there were 30,000 SARs outstanding at an exercise price per share of $0.00001. As of December 31, 2020 and 2019, the Company had recorded liabilities of $0.7 million and $0.4 million related to these SARs based on their fair value of $20.28 and $12.98 per share as of December 31, 2020 and 2019, respectively. The Company recognized expense for the SARs in the consolidated statements of operations and comprehensive loss under selling, general and administrative of $0.3 million and $0.02 million during the years ended December 31, 2020 and 2019. 2013 Share Option Plan In 2013, we adopted the 2013 Equity Incentive Plan (the “Plan”), which provides for grants of stock options to attract and retain employees, directors, officers, and consultants. As of December 31, 2020, there were 11,458,989 shares authorized for issuance under the Plan, of which 2,746,089 shares were available for grant. Share options can be granted with an exercise price less than, equal to or greater than the shares’ fair market value at the date of grant. All options vest over the earlier of 4 years of service from grant or start of service, with typically 25% becoming exercisable on the first anniversary of the grant or start of service and the balance becoming exercisable in equal monthly portions over the following 36 months. The following table summarizes stock option activity related to the plans during the years ended December 31, 2020 and 2019: Number of Average Remaining Intrinsic (Years) (In thousands) Balances as of December 31, 2018 5,565,292 $ 2.88 6.68 $ 59,146 Options granted 1,135,148 9.29 Options exercised (24,750 ) 1.33 Options forfeited (120,001 ) 6.65 Options expired (651,276 ) 2.78 Balances as of December 31, 2019 5,904,413 $ 4.05 6.94 $ 54,100 Options granted 2,328,385 8.67 Options exercised (7,813 ) 5.36 Options forfeited (826,488 ) 8.62 Options expired (191,453 ) 6.92 Balances as of December 31, 2020 7,207,044 $ 4.94 6.75 $ 110,552 Options exercisable—December 31, 2020 4,693,313 $ 3.16 5.51 $ 80,334 The aggregated intrinsic value represents the difference between the exercise price and the fair value of Ordinary Shares. The total aggregate intrinsic value of options exercised during the years ended December 31, 2020 and 2019 was $0.1 million and $0.3 million, respectively. The weighted-average grant-date fair value of options granted during the years ended December 31, 2020 and 2019 was $8.32 and $7.92 per share, respectively. Stock-based compensation expense for all equity arrangements for the years ended December 31, 2020 and 2019 was as follows (in thousands): Years Ended December 31, 2020 2019 Cost of revenue $ 2,271 $ 2,230 Research and development 4,313 2,835 Sales and marketing 639 475 General and administrative 820 689 Total stock-based compensation expense $ 8,043 $ 6,229 As of December 31, 2020 and 2019, there was approximately $19.5 million and $13.8 million of total unrecognized stock based compensation expense, related to unvested options granted to employees under the Company’s stock option plan that is expected to be recognized over a weighted average period of 1.4 years and 1.3 years, respectively. Performance Awards During the year ended December 31, 2019, 249,605 performance-based awards at a weighted average grant date fair value of $7.84 were granted to certain individuals with conditions that include specific sales and fundrai sing targets. As of December 31, 2020, it was determined that all of these awards met their performance conditions, and the Company recognized a total ex unrecognized stock-based compensation expense related to these performance-based awards. During the year ended December 31, 2020, no additiona Fair Value of Options The fair values of options granted during the period wer e determined using a Black-Scholes model. The following principal assumptions were used in the valuation: Fair Value of Ordinary Shares erlying the stock option awards was determined by the Board of Directors (“the Board”). Given the absence of a public trading market, the Board considered numerous objective and subjective factors to determine the fair value of the Company’s Ordinary Shares at each meeting at which awards were approved. These factors included, but were not limited to (i) contemporaneous third party valuations of Ordinary Shares; (ii) the lack of marketability of Ordinary Shares; (iii) stage and development of the Company’s business; (iv) general economic conditions; and (vi) the likelihood of achieving a liquidity event, such as an IPO or sale of the Company, given prevailing market conditions. To evaluate the fair value of the underlying shares for grants between two independent valuations and after the last independent valuation, a linear interpolation framework was used to evaluate the Volatility d on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading its Risk-free Interest Rate e based on US Treasury yields in effect at the grant date for notes with comparable terms as the awards. Expected Term nt historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior, the Company determines the expected term based on the average period the stock options are expected to remain outstanding. For stock options, expected ter Dividend Yield d dividend rate is zero as the Company has not declared or paid any cash dividends and does not anticipate to do so in the foreseeable future. Years Ended December 31, 2020 2019 Expected term (in years) 4.86 – 6.25 5.61 Expected volatility (%) 50.29 – 52.45 50.40 – 51.37 Risk-free interest rate (%) 0.30 – 1.75 1.42 – 1.88 Fair value of Ordinary Shares $ 10.58 – 19.96 $ 13.21 – 13.52 Dividend yield — — Warrants We issued warrant certificates to certain counterparties to subscribe in its Ordinary Shares. During the years ended December 31, 2020 and 2019, 51,859 paid-in The 2019 Convertible Loan Notes were co nverted into Ordinary Shares during 2019 at a lower price than was paid by certain shareholders who had invested prior to the issuance of the 2019 Conv non-cash During the year ended December 31, 2019, the Company issued 5,246 warran ts for goods and services, which were recognized as an expense in selling, general and administrative expense on the consolidated statements of oper paid-in The below warrants are equity classified and exercisable as of December 31, 2020 and 2019. Investor Warrants in connection with the 8.0% Convertible Notes were excluded from the below table as they were classified as liabilities. A summary of the Company’s outstanding warrants as of December 31, 2020 and 2019 are presented below Number of Weighted- Weighted- Balances as of December 31, 2018 678,232 $ 7.05 7.60 Warrants issued 304,864 7.44 Warrants exercised (2,757 ) 0.00 Warrants cancelled — — Balances as of December 31, 2019 980,339 $ 7.19 7.29 Warrants issued 51,859 10.30 Warrants exercised (5,523 ) 1.26 Warrants cancelled (13,572 ) 11.44 Balances as of December 31, 2020 1,013,103 $ 7.33 6.45

Related Party Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party The Company formed HRT, a joint venture with Hengtong Optic-Electric Co., Ltd. in 2017, which was recognized by the Company as an equity method investment. During the three and six months ended June 30, 2021, we made no sales to HRT. During the three and six months ended June 30, 2020, we made sales to HRT of $2.5 million. As of June 30, 2021 and December 31, 2020, the balance owed by the joint venture amounted to $0.4 million and $3.3 million, respectively, and is included in accounts receivable in the accompanying balance sheets. As of June 30, 2021, there was no balance owed to the joint venture. The Company engages two affiliate entities of the Company’s directors for consulting and administrative services. The fees incurred for these services were immaterial for the three and six months ended June 30, 2021 and 2020. As of June 30, 2020 and December 31, 2020, the amounts included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets were not considered material.	12. Related Party Transactions The Company formed HRT, a joint venture with Hengtong Optic-Electric Co., Ltd. in 2017, which was recognized by the Company as an equity method investment. During the years ended December 31, 2020 and 2019, we made sales to HRT of llion, respectively, and is included in accounts receivable in the accompanying balance sheets. The Company engages two affiliate entities of the Company’s directors for consulting and administrative services. For the years ended December 31, 2020 and 2019, the Company incurred $0.8 million and $1.9 million in fees for these services, respectively. As of December 31, 2020 and 2019, the amounts included in accounts payable and accrued expenses in the accompanying balance shee

Leases

Leases	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Leases	12. Leases The weighted average remaining lease term was 3 years for operating leases as of June 30, 2021. The weighted average discount rate was 6% for operating leases as of June 30, 2021. Finance lease Three Months Ended Six Months Ended 2021 2020 2021 2020 (Unaudited) (Unaudited) Operating Lease Cost: Fixed lease cost $ 292 $ 213 $ 505 $ 426 Variable lease cost 36 81 119 121 Total operating lease cost $ 328 $ 294 $ 624 $ 547 The supplemental cash flow information related to our operating leases is as follows (in thousands): Six Months Ended 2021 2020 Supplemental Cash Flow Information : Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 462 $ 454 Operating cash flows for finance leases $ — $ 12 Financing cash flows for finance leases $ — $ 933 Right-of-use Right-of-use $ 2,187 $ — There are no finance lease liabilities as of June 30, 2021. Maturities of operating lease liabilities as of June 30, 2021, are as follows (in thousands): Operating Leases 2021 (for the remaining period) $ 582 2022 1,239 2023 931 2024 437 2025 327 Thereafter 394 Total lease obligation $ 3,910 Less: Imputed interest (408 ) Total lease liabilities $ 3,502 Less: Current lease liabilities (1,020 ) Total non-current $ 2,482	13. Leases We have operating leases for office space and finance leases for manufacturing equipment. These leases have remaining lease terms of 1 years to 4 years. Some leases include extension options for up to 5 years. These options are included in the lease term when it is reasonably certain that the option will be exercised. The weighted average remaining lease term was 3 years for operating leases as of December 31, 2020. The weighted average discount rate was 6% for operating leases as of December 31, 2020. The components of lease cost for the year ended December 31, 2020, were as follows (in thousands): Years Ended December 31, 2020 2019 Operating Lease Cost: Fixed lease cost $ 851 777 Variable lease cost 154 253 Total operating cost $ 1,005 $ 1,030 Total lease cost $ 1,391 $ 1,533 Other information related to leases was as follows (in thousands): Years Ended December 31, 2020 2019 Supplemental Cash Flow Information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 916 $ 756 Operating cash flows for finance leases $ 15 $ 115 Financing cash flows for finance leases $ 1,192 $ 1,215 Right-of-use Right-of-use $ — $ 1,158 There are no finance lease liabilities as of December 31, 2020. Maturities of operating lease liabilities as of December 31, 2020, were as follows (in thousands): Operating Leases Year Ending December 31: 2021 $ 682 2022 613 2023 456 2024 121 Total lease obligation $ 1,872 Less: Imputed interest (149 ) Total lease liabilities $ 1,723 Less: Current lease liabilities (596 ) Total non-current $ 1,127

Commitment and Contingencies

Commitment and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Legal Contingencies From time to time, we are a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. We apply accounting for contingencies to determine when and how much to accrue for and disclose related to legal and other contingencies. Accordingly, we disclose contingencies deemed to be reasonably possible and accrue loss contingencies when, in consultation with legal advisors, it is concluded that a loss is probable and reasonably estimable. Although the ultimate aggregate amount of monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, management believes that as of June 30, 2021 there are no litigations pending that could have, individually and in the aggregate, a material adverse effect on our financial position, results of operations or cash flows. Financial Commitments In the ordinary course of business, we make commitments to third-party suppliers for various research and development activities. As of June 30, 2021 and December 31, 2020, we had $8.1 million and $3.0 million, respectively, in contractual obligations for which we have not yet received the services.	14. Commitments and Contingencies Legal Contingencies From time to time, we are a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. We apply accounting for contingencies to determine when and how much to accrue for and disclose related to legal and other contingencies. Accordingly, we disclose contingencies deemed to be reasonably possible and accrue loss contingencies when, in consultation with legal advisors, it is concluded that a loss is probable and reasonably estimable. Although the ultimate aggregate amount of monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, management believes that as of December 31, 2020 there are no litigations pending that could have, individually and in the aggregate, a material adverse effect on our financial position, results of operations or cash flows. Financial Commitments In the ordinary course of business, we make commitments to third-party suppliers for various research and development activities. As of December 31, 2020 and 2019, we had $3.0 million and $3.3 million, respectively, in contractual obligations for which we have not yet received the services.

Defined Contribution Plan

Defined Contribution Plan	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Defined Contribution Plan	14. Defined Contribution Plan We have defined contribution plans, under which we contribute based on a percentage of the employees’ elected contributions. We will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognized within selling, general and administrative expenses and research and development in the condensed consolidated statements of operations and comprehensive loss. Defined contributions were $0.2 million and $0.1 million for the three months ended June 30, 2021 and 2020, respectively. Defined contributions were $0.4 million and $0.3 million for the six months ended June 30, 2021 and 2020, respectively.	15. Defined Contribution Plan We have defined contribution plans, under which we contribute based on a percentage of the employees’ elected contributions. We will have no legal or constructive obligation to pay further amounts. The contributions made by us for the years ended December 31, 2020 and 2019 was $0.5 million and $0.4 million, respectively.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	15. Supplemental Non-cash Six Months Ended 2021 2020 (Unaudited) Supplemental Cash Flow Information: Interest pai d $ 271 $ 45 Income tax paid $ 210 $ 80 Non-cash Right-of-use $ 2,187 $ — $ 2,187 $ 0 Non-cash Unpaid property and equipment received $ 1,163 $ 295 Non-cash Unpaid deferred transaction cost s $ 5,201 $ — Forgiveness of Paycheck Protection Program loan $ (2,860 ) $ — $ 2,341 $ —	16. Supplemental Cash Flow Information Non-cash Years Ended 2020 2019 Supplemental disclosure Cash payments for: Interest paid $ 47 $ 506 Income tax paid $ 313 $ 352 Schedule for noncash operating activities Right-of-use $ — $ 1,158 $ — $ 1,158 Schedule for noncash investing activities Unpaid property and equipment received $ 166 $ 397 Unpaid balance related to the Trutouch Asset Acquisition 500 — $ 666 $ 397 Schedule for noncash financing activities Conversion of note payable to Ordinary Shares $ — $ 18,244 Issuance of Ordinary Shares related to the Trutouch Asset Acquisition 2,298 — Non-cash — 995 Non-cash — 1,838 $ 2,298 $ 21,077

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Subsequent Events	16. Subsequent Subsequent events have been evaluated through the date that these financial statements were issued. Rockley Photonics Holdings Limited (“HoldCo”) was formed on March 11, 2021 for the purpose of effecting a merger or other similar business combination with one or more operating businesses. HoldCo had neither engaged in any operations nor generated significant revenue through June 30, 2021. On March 19, 2021, the Company entered into a definitive agreement to combine with SC Health Corporation (“SC Health”), a publicly traded special purpose acquisition company. The transaction resulted in Rockley becoming a publicly traded company. On July 22, 2021, Rockley Photonics Holdings Limited’s Form S-4 Notice of Effectiveness from the Securities and Exchange Commission (“SEC”). On August 9, 2021, among other things, we proposed to the High Court of the United Kingdom a transfer scheme of arrangement under Part 26 of the Companies Act pursuant to which our shareholders exchanged all of Rockley Photonics Limited shares for Rockley Photonics Holdings Limited Ordinary Shares, at a conversion price of $10.00 per share. The transfer is conditional upon the approval of the Business Combination Agreement, the Business Combination and the Plan of Merger by SC Health shareholders. The Business Combination was consummated on August 11, 2021 and Rockley Photonics Holdings Limited became a publicly traded company listed on the NYSE under the symbol “RKLY”. Subsequent to the consummation of the Business Combination, the Rockley Photonics Limited and its subsidiary entities became a wholly owned subsidiary of Rockley Photonics Holdings Limited. Immediately following the completion of the Business Combination and the related organizational transactions on August 11, 2021, the following took place: Rockley Photonics Holdings Limited received $126.9 million in proceeds, net of underwriting discounts and commissions. The shareholders of SC Health and Rockley Photonics Limited hold 12,339,650 and 103,916,607 shares, or approximately 9.8% and 82.3% ownership interest in Rockley Photonics Holdings Limited, respectively. The Company’s issued and outstanding convertible loan notes (other than certain convertible notes issued in connection with the 2020 Term Facility Loan, of which 30% were converted to Ordinary Shares of HoldCo and 70% were converted to convertible notes of HoldCo that mature on August 31, 2022), inclusive of interest accrued thereon, converted into Ordinary Shares of HoldCo at a conversion price of $10.00 per share. The Company’s issued and outstanding warrants were converted to Ordinary Shares of HoldCo. In connection with the transaction, we incurred legal, accounting, and other professional fees in connection with the completion of the Business Combination. Through August 12, 2021, we have paid approximately $29.3 million of these expenses. As of August 12, 2021, approximately $14.8 million of these expenses remained unpaid.	17. Subsequent Events Subsequent events have been evaluated through April 2, 2021, which is the date that the financial statements were issued. During the year ended December 31, 2020, 250,000 restricted stock units (“RSUs”) were offered to our three executives. Each RSU has a performance-based grant criteria that the Company completes a SPAC transaction. As of December 31, 2020, it was determined that none of these awards meet the performance condition and no expense was recognized in relation to these awards. In 2021, the Company issued convertible notes bearing interest at a rate of 5.0% per annum. The terms of the notes are similar to the 2020 Convertible Notes. We received $25.0 million on January 5, 2021, $10.0 million on January 13, 2021, and $30.0 million on January 18, 2021. We also received $11.4 million in connection with the 2020 Term Facility Loan on February 19, 2021. On March 19, 2021, the Company entered into a definitive agreement to combine with SC Health Corporation, a publicly traded special purpose acquisition company. The transaction will result in Rockley becoming a publicly traded company on the NYSE under the symbol “RKLY” and values the Company at a pro forma enterprise value of $1.2 billion.
Rockley Photonics Holdings Limited
Subsequent Events	3. Subsequent Events Subsequent events have been evaluated through the date that these financial statements were issued. In relation to the Business Combination, on July 22, 2021, HoldCo’s Form S-4 The Business Combination was consummated on August 11, 2021 and HoldCo became a publicly traded company listed on the New York Stock Exchange (“NYSE”) under the symbol “RKLY.” Subsequent to the consummation of the Business Combination, Rockley and its subsidiary entities became a wholly owned subsidiary of HoldCo.

Description of Business and S_2

Description of Business and Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Preparation	Basis of Presentation and Preparation The accompanying unaudited condensed consolidated financial statements have been prepared by the Company, and reflect all adjustments, consisting only of normal recurring adjustments, that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations, comprehensive income, cash flows and shareholders’ equity for the interim periods presented. The statements have been prepared in accordance with GAAP for interim financial information. Accordingly, these statements do not include all information and footnotes required by GAAP for annual consolidated financial statements, and should be read in conjunction with our audited consolidated financial statements and notes thereto in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2020 included in the Rockley Photonics Holdings Limited’s Registration Statement on Form S-4 No. 333-255019), The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include, but are not limited to, revenue recognition, reserves and allowances; valuation of intangibles; product warranties; employee compensation and benefit accruals; stock-based compensation; loss contingencies; income taxes and fair value measurements. Actual results could differ materially from those estimates. Management’s estimates include, as applicable, the anticipated impacts of the COVID-19	Basis of Presentation The consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).
Going Concern	Going Concern The Company has incurred net losses since inception, has an accumulated deficit of $328.2 million as of June 30, 2021 and negative cash flow from operations of $54.5 million for the six months ended June 30, 2021 and expects to incur losses from operations for the foreseeable future. As of June 30, 2021, the Company had cash and cash equivalents of approximately $35.4 million. The Company’s ability to meet its obligations in the ordinary course of business is dependent on its ability to obtain additional financing. As a result, there is substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Our future liquidity needs, and ability to address those needs, will largely be determined by our ability to obtain additional financing on terms acceptable to us. We will continue to seek additional capital through the sale of debt or equity, or other arrangements, however, there can be no assurance that we will be able to raise
Global Pandemic	Global Pandemic The COVID-19 COVID-19 The COVID–19 pandemic has adversely impacted our operational efficiency and caused delays in operational activities. During the second quarter of 2021, we continue to take cautious steps to protect our workforce, support community efforts, and follow local government guidelines. Certain key laboratory employees and facilities have continued internal testing and laboratory work to the extent necessary to service customer commitments. The remaining non-essential
Recently Adopted Accounting Pronouncements and Accounting Pronouncements Issued but Not Yet Adopted	Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU 2018-13, On June 16, 2016, the FASB issued ASU No. 2016-13, available-for-sale In August 2020, the FASB issued ASU 2020-06, 470-20) 815-40):	Recently Adopted Accounting Pronouncements In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (Topic 815) 2018-02 In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (“Topic 820”): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement Accounting Pronouncements Issued but Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, 2019-12 On June 16, 2016, the FASB issued ASU No. 2016-13, available-for-sale non-public
Principles of Consolidation		Principles of Consolidation The consolidated financial statements include Rockley Photonics Limited and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates		Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates and assumptions, including those related to (i) revenue recognition including variable consideration, (ii) useful lives and recoverability of property and equipment and long-lived assets, (iii) incremental borrowing rates on the Company’s finance and operating leases, (iv) valuation of our convertible loan notes, (v) valuation allowances for income taxes, (vi) stock-based compensation including the valuation of Ordinary Shares, (vii) valuation of warrants and (viii) contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could materially differ from these estimates, including impacts from the COVID-19
Cash and Cash Equivalents		Cash and Cash Equivalents Cash and cash equivalents include short-term, highly liquid investments with an original maturity of three months or less.
Property and Equipment, Net		Property and Equipment, Net Property and equipment are recorded at cost and presented net of accumulated depreciation and amortization. Significant additions or improvements extending the useful life of an asset are capitalized, while repairs and maintenance costs are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the term of the lease or the useful life of the assets. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the related assets. Computer equipment 3 years Lab equipment 3 years Furnitures and fixtures 4 years Leasehold improvements Shorter of the lease term and the useful life
Impairment of Long-Lived Assets		Impairment of Long-Lived Assets We evaluate our long-lived assets, such as property and equipment, and right-of-use The Company tests other intangible assets not subject to amortization for impairment annually and more frequently if events or changes in circumstances between annual tests indicate that it is more likely than not that the asset is impaired. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets. To date, no such impairment losses have been recorded.
Revenue Recognition		Revenue Recognition We generate our revenue principally from development services, which entails developing the customer-specific designs of photonics chips. Revenue is recognized when control of promised goods and services are transferred to customers in an amount that reflects the expected consideration in exchange for those products and services. This principle is achieved by applying the following five-step approach: • Identification of the contract with a customer – • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations in the contract • Recognition of revenue when or as performance obligations are satisfied Contract balances 30-45 Costs to obtain and fulfill a contract –
Foreign Currency Transactions		Foreign Currency Transactions The Company’s reporting currency is the U.S. dollar and the functional currency of the Company’s foreign subsidiaries is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into the functional currency with any related gain or loss recorded in earnings. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in realized and unrealized losses/(gains) on foreign currency in the accompanying consolidated statements of operations and comprehensive loss.
Segment Information		Segment Information Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the CODM. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, the Company determined that it has one operating and reportable segment.
Net Loss Per Share		Net Loss Per Share Basic earnings per share is calculated using our weighted-average outstanding Ordinary Shares. Diluted earnings per share is calculated using our weighted-average outstanding Ordinary Shares including the dilutive effect of outstanding equity instruments as determined under the treasury stock method. For periods in which we report net losses, diluted net loss per ordinary share attributable to ordinary stockholders is the same as basic net loss per ordinary share attributable to ordinary stockholders, because all potentially dilutive Ordinary Shares are anti-dilutive.
Concentration of Risk		Concentration of Risk Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable. We maintain cash balances at financial institutions that management believes are high-credit, quality financial institutions, where deposits, at times, exceed the Federal Deposit Insurance Corporation limits.
Accounts Receivable		Accounts Receivable Accounts receivable is recorded at the invoiced amount and do not bear interest. We assess the need for an allowance for doubtful accounts based upon an analysis of past credit history and the current financial condition of its customers, as well as the consideration of expected trends based upon characteristics of the accounts and general economic conditions. Account balances are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts is insignificant as of December 31, 2020 and 2019.
Equity Method Investments		Equity Method Investments Equity method investments are all entities over which we have significant influence but not control or joint control. Under the equity method of accounting, the investments are initially recognized at cost and adjusted thereafter to recognize the Company’s share of the post-acquisition profits or losses of the investee in the consolidated statement of operations and comprehensive loss. Earnings and losses of equity method investments are based on the most recently available financial statements of the investee. Basis differences between the cost of an equity method investment and the underlying equity in the long-lived assets are amortized over the estimated economic useful life of the underlying long-lived asset. We periodically review our equity method investments for impairment and record a reduction in the carrying value, if and when necessary. To date, no such impairment losses have been recorded.
Stock-Based Compensation		Stock-Based Compensation We measure compensation expense for all stock-based awards based on the estimated fair value of the awards on the date of grant. Compensation expense is generally recognized as expense on a straight-line basis over the service period based on the vesting requirements. We recognize forfeitures as they occur. We estimate the fair value of stock options granted to employees using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (i) the fair value of Ordinary Shares, (ii) the expected stock price volatility, (iii) the expected term of the award, (iv) the risk-free interest rate and (v) expected dividends. We measure nonemployee awards at their fair value on the adoption date of ASU No. 2018-07. No. 2018-07 We granted options and restricted stock units which vest on the satisfaction of both a specific performance condition and a service-based condition.
Warrants		Warrants We determine the accounting classification of warrants, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, 480-10, 815-40, 815-40, 815-40 We issue warrants to purchase Ordinary Shares for goods and services received and these warrants are measured at their fair values upon issuance. Where vendors are issued warrants, the fair value of the services are determined by the fair value of the warrants issued. This fair value is measured at the grant date and excludes the impact of non-market paid-in We may also issue warrants to purchase Ordinary Shares in conjunction with equity financing rounds. Such warrant issuances are recognized as equity issuance costs, with a corresponding credit in additional paid-in paid-in We issued the liability classified warrants during the year ended December 31, 2020 that are embedded with the 8.0% Convertible Notes. Refer to Note 7, Long Term Debt for details.
Leases		Leases Our lease portfolio is comprised of two major classes: real estate leases, which are the majority of our leased assets, are accounted for as operating leases and a manufacturing equipment lease accounted for as a finance lease on the consolidated balance sheet. We classify leases as either operating or financing. We determine if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all the economic benefits from and have the ability to direct the use of the asset. Operating lease assets are included under other non-current right-of-use ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments is used. The operating lease ROU asset includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease We elected, as an accounting policy for leases of real estate, to account for lease and non-lease Variable payments, such as common area charges, maintenance, insurance and taxes, are primarily based on the amount of space occupied. These payments in the Company’s leases are not dependent on an index or a rate and are excluded from the measurement of the lease liabilities and recognized in the consolidated statements of operations and comprehensive loss in the period in which the obligation for those payments is incurred. The Company remeasures lease payments when the contingency underlying such variable payments is resolved such that some or all of the remaining payments become fixed.
Cost of Revenue		Cost of Revenue Our cost of revenue consists of costs related to the Company’s development services which includes cost of materials, cost associated with packaging and assembly, testing and shipping, cost of personnel, including stock-based compensation, and equipment associated with manufacturing support, logistics and quality assurance, overhead and occupancy costs.
Research and Development Expenses		Research and Development Expenses Research and development expense consists primarily of personnel costs for engineers and third parties engaged in the design and development of products, software and technologies, including salary, bonus and share-based compensation expense, project material costs, services and depreciation. The Company expenses research and development costs as they are incurred .
Selling, General and Administrative Expenses		Selling, General and Administrative Expenses Selling, general and administrative expenses consist of human capital related expenses for employees involved in general corporate functions, including executive management and administration, accounting, finance, tax, legal, information technology, marketing, and human resources; depreciation expense and rent relating to facilities; travel costs; professional fees; and other general corporate costs. Human capital expenses primarily include salaries, benefits, bonuses and stock-based compensation. As we continue to grow as a company, we expect that our selling, general and administrative costs will increase on an absolute dollar basis.
Fair Value of Financial Instruments and Fair Value Measurements		Fair Value of Financial Instruments and Fair Value Measurements The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: Level 1 Inputs: Unadjusted quoted prices for identical assets or instruments in active markets. Level 2 Inputs: Quoted prices for similar instruments in active markets and quoted prices for identical or similar instruments in markets that are not active and model derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 Inputs: Significant inputs into the valuation model are unobservable. As permitted under the FASB, ASC 825, Financial Instruments (“ASC 825”) Fair value is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not available, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments’ complexity. For debt instruments for which we have not elected fair value accounting (i.e. paycheck protection program), fair value is based on the present value of expected future cash flows and assumptions about the then-current market interest rates as of the reporting period and the creditworthiness of the Company. The carrying value of these debt instruments approximates fair value as the stated interest rate approximates market rates currently available to us. For all debt instruments, including any for which we have elected fair value accounting, the Company classifies interest that has been accrued during each period as Interest expense on the consolidated statements of operations and comprehensive loss. The recorded amounts of cash, accounts receivable, trade payable, and accrued expenses and other liabilities approximate the fair values principally because of their short-term nature.
Income Taxes		Income Taxes Deferred income taxes are provided on a liability method, whereby deferred income tax assets are recognized for deductible temporary differences, operating losses, and tax loss carryforwards, and deferred income tax liabilities are recognized for taxable temporary differences. Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their tax bases and are stated at enacted tax rates expected to be in effect when taxes are actually paid or recovered. Deferred income tax assets are reduced by a valuation allowance when, considering all sources of taxable income, in the opinion of management, it is more likely than not that some portion or all of the deferred income tax assets will not be realized. Deferred income tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company recognizes the income tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by taxing authorities, based on the technical merits of the position. The income tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.
Accounting Pronouncements Issued but Not Yet Adopted	Accounting Pronouncements Issued but Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, simplifies areas including franchise taxes that are partially based on income, transactions with a government that result in a step up in the tax basis of goodwill, the incremental approach for intraperiod tax allocation, interim period income tax accounting for year-to-date laws 2019-12 2020

Description of Business and S_3

Description of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Disclosure Of Useful Lives Of Property Plant And Equipment	Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the related assets. Computer equipment 3 years Lab equipment 3 years Furnitures and fixtures 4 years Leasehold improvements Shorter of the lease term and the useful life

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table depicts the disaggregation of revenue by geography, consistent with how we evaluate its financial performance (in thousands): Three Months Ended June 30 Six Months Ended June 30, 2021 2020 2021 2020 United States $ 2,195 $ 5,423 $ 3,966 $ 12,086 Rest of World $ — $ 2,458 $ — $ 2,458 Total revenue $ (2,195 ) $ 7,881 $ 3,966 $ 14,544	The following table depicts the disaggregation of revenue by geography, consistent with how we evaluate its financial performance (in thousands): December 31, 2020 2019 United States $ 17,037 $ 13,783 Rest of World 5,306 6,709 Total revenue $ 22,343 $ 20,492
Schedules of Concentration of Risk, by Customer	The following tables summarize our significant customers as of June 30, 2021 and December 31, 2020 and for the three and six months ended June 30, 2021 and 2020: Revenue Three Months Ended June 30 Six Months Ended June 30, 2021 2020 2021 2020 (Unaudited) (Unaudited) Customer A 100 % 69 % 100 % 83 % Customer B — % 31 % — % 17 % Accounts Receivable As of June 30, 2021 December 31, 2020 Customer A 81 % 33 % Customer B 17 % 67 %	The following is our significant customers as of and for the years ended December 31, 2020 and 2019: Revenue Accounts December 31, December 31, 2020 2019 2021 2020 Customer A 76 % 67 % 33 % 55 % Customer B 24 % 33 % 67 % 45 %

Equity Method Investment (Table

Equity Method Investment (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Summary of Investments	The following table summarizes our investment in HRT for the six months ended June 30, 2021 (in thousands): June 30, 2021 (Unaudited) Beginning balance $ 5,202 Investment in HRT — Remeasurement gain on HRT 269 Share of loss of HRT (760 ) Ending balance $ 4,711	For the years ended December 31, 2020 and 2019, the accompanying consolidated balance sheets and statements of operations and comprehensive loss reflected the following (in thousands): December 31, 2020 2019 As of January 1, $ 1,486 $ 2,767 Investment in HRT 4,990 — Share of loss of HRT (1,274 ) (1,281 ) As of December 31, $ 5,202 $ 1,486

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value, by Balance Sheet Grouping	Our financial assets are considered Level 1 in the fair value hierarchy and measured at fair value, were as follows (in thousands): As of June 30, December 31, (Unaudited) Assets Cash equivalents Money market funds $ 11,316 $ 11,516 All of our financial liabilities are considered Level 3 in the fair value hierarchy, where inputs to the valuation techniques used to measure fair value were considered unobservable. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the liability. The financial liabilities subject to fair value measurement on a recurring basis, were as follows (in thousands): As of June 30, December 31, (Unaudited) Financial Liabilities 3.00% – 2020 Convertible Notes $ 36,214 $ 32,106 8.00% – 2020 Convertible Notes 17,038 14,789 2020 Term Facility Loan 39,970 25,049 5.00% – $50.0 Million Convertible Notes 11,220 — 5.00% – $25.0 Million Convertible Notes 43,070 — 5.00% – $30.0 Million Convertible Notes 46,816 — Total financial liabilities $ 194,328 $ 71,944	Our financial assets as of December 31, 2020 and 2019 are considered Level 1 in the fair value hierarchy and measured at fair value as follows: December 31, 2020 2019 Assets Money market funds $ 11,516 $ 12,343 All of our financial liabilities as of December 31, 2020, and 2019, are considered Level 3 in the fair value hierarchy, where inputs to the valuation techniques used to measure fair value were considered unobservable. The fair value of our liabilities are as follows (in thousands): December 31, 2020 2019 Liabilities 3.0% – 2020 Convertible Notes $ 32,106 — 8.00% – 2020 Convertible Notes 14,789 — 2020 Term Facility Loan 25,049 — 2017 Term Loan — 1,952 Total financial liabilities $ 71,944 $ 1,952
Fair Value Measurement Inputs and Valuation Techniques	As of June 30, 2021, we measured fair value using a binomial lattice model (which is discussed in further detail below) with the following significant inputs: Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 48.45 % Conversion price discount 25 % Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 35 % Conversion price discount 40 % Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 35 % Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 48.4 % Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 48.4 % Fair Value per share of Ordinary Shares $ 24.70 Risk-free interest rate 0.03 % Expected volatility 55 % Expected term, in years 0.10 Discount yield 48.4 %	Fair Value per share of Ordinary Shares $20.28 Risk-free interest rate 0.08% - 0.10 % Expected volatility 55 % Expected term, in years 0.14 - 4.19 Discount yield 48.4 % Conversion price discount 25% - 40 % Fair Value per share of Ordinary Shares $20.28 Risk-free interest rate 0.08% - 0.52 % Expected volatility 55 % Expected term, in years 0.14 - 6.14 Discount yield 35 % Conversion price discount 25% - 40 % Fair Value per share of Ordinary Shares $20.28 Risk-free interest rate 0.21 % Expected volatility 55 % Expected term, in years 0.14 - 4.13 Discount yield 35 %
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis	We recorded a loss of $1.1 million and $4.1 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with the subsequent fair value remeasurement of the 3.00% Convertible Notes, as follows (in thousands): Fair value at December 31, 2020 $ 32,106 Plus: Loss from change in fair value $ 4,108 Fair value at June 30, 2021 $ 36,214 We recorded a loss of $0.5 million and $2.2 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with the subsequent fair value remeasurement of the 8.0% Convertible Notes, as follows (in thousands): Fair value at December 31, 2020 $ 14,789 Plus: Loss from change in fair value $ 2,249 Fair value at June 30, 2021 $ 17,038 We recorded a loss of $1.2 million and $14.9 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with the subsequent fair value remeasurement of 2020 Term Facility Loan, as follows (in thousands): Fair value at December 31, 2020 $ 25,049 Plus: Loss from change in fair value $ 14,921 Fair value at June 30, 2021 $ 39,970 We recorded a loss of $0.3 million and $0.9 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with the subsequent fair value remeasurement of 5.00% – $50.0 Million Convertible Note, as follows (in thousands): Fair value at January 11, 2021 $ 10,274 Plus: Loss from change in fair value $ 946 Fair value at June 30, 2021 $ 11,220 We recorded a loss of $1.3 million and $5.5 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with subsequent fair value remeasurement of the 5.00% – $25.0 Million Convertible Notes, as follows (in thousands): Fair value at December 31, 2020 $ 37,592 Plus: Loss from change in fair value $ 5,478 Fair value at June 30, 2021 $ 43,070 We recorded a loss of $1.4 million and $8.4 million for the three and six months ended June 30, 2021, respectively from a change in fair value of debt in connection with the subsequent fair value remeasurement of the 5.00% – $30.0 Million Convertible Notes, as follows (in thousands): Fair value at January 11, 2021 $ 38,403 Plus: Loss from change in fair value $ 8,413 Fair value at June 30, 2021 $ 46,816	For the year ended December 31, 2020, we recorded a $10.8 million loss from change in fair value of debt in connection with the initial issuance and subsequent fair value remeasurement of the 3.0% Convertible Notes, as follows (in thousands): Fair value at March 9, 2020 $ 21,281 Plus: Loss from change in fair value 10,825 Fair value at December 31, 2020 $ 32,106 For the year ended December 31, 2020, we recorded a $ 4.4 Fair value at February 19, 2020 $ 10,415 Plus: Loss from change in fair value 4,374 Fair value at December 31, 2020 $ 14,789 For the year ended December 31, 2020, we recorded a $1.7 million loss from change in fair value of debt in connection with the initial issuance and subsequent fair value remeasurement of 2020 Term Facility Loan, as follows (in thousands): Fair value at September 29, 2020 $ 23,320 Plus: Loss from change in fair value 1,729 Fair value at December 31, 2020 $ 25,049

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Cash and Cash Equivalents	Cash and cash equivalents Cash and cash equivalents balances were concentrated by location as follows: As of June 30, December 31, (Unaudited) United Kingdom 92 % 96 % United States 7 % 3 % Other 1 % 1 %	Cash and cash equivalents Our cash and cash equivalents balances as of December 31, 2020 and 2019 were concentrated by location as follows: December 31, 2020 2019 United Kingdom 96 % 95 % United States 3 % 4 % Other 1 % 1 %
Schedule of Other Receivables	Other receivables (in thousands As of June 30, December 31, (Unaudited) R&D tax credit receivable $ 21,911 $ 17,412 Grants receivable 573 — VAT receivable 549 607 Other receivable 4 5 Total other receivables $ 23,037 $ 18,024	Other receivables Other receivables consist of the following (in thousands): As of December 31, 2020 2019 R&D tax credit receivable $ 17,412 $ 14,731 Grants receivable — 239 VAT receivable 607 886 Other receivable 5 93 Total other receivables $ 18,024 $ 15,949
Schedule of Property, Plant and Equipment	Property and equipment, net (in thousands): As of June 30, December 31, (Unaudited) Computer equipment $ 1,744 $ 1,218 Lab equipment 10,081 7,607 Motor vehicles 31 31 Furniture and fixtures 265 265 Leasehold improvements 704 704 Assets under construction 561 27 Total property and equipment $ 13,386 $ 9,852 Less: accumulated depreciation (7,162 ) (5,802 ) Total property and equipment, net $ 6,224 $ 4,050	Property and equipment, net consisted of the following (in thousands): As of December 31, 2020 2019 Computer equipment $ 1,218 $ 1,020 Lab equipment 7,607 5,614 Motor vehicles 31 31 Furnitures and fixtures 265 265 Leasehold improvements 704 704 Assets under construction 27 587 Total property and equipment $ 9,852 $ 8,221 Less: accumulated depreciation (5,802 ) (3,561 ) Total property and equipment, net $ 4,050 $ 4,660
Finance Lease, Right-Of-Use Assets	Finance lease right-of-use net As of June 30, December 31, (Unaudited) Finance lease right-of-use $ 2,966 $ 2,966 Less: accumulated amortization (1,020 ) (834 ) Total finance lease right-of-use assets, net $ 1,946 $ 2,132	Finance lease right-of-use As of December 31, 2020 2019 Finance lease right-of-use $ 2,966 $ 3,105 Less: accumulated amortization (834 ) (485 ) Total finance lease right-of-use assets, net $ 2,132 $ 2,620
Schedule of Intangible Assets, Net	Intangible assets, net (in thousands): As of June 30, December 31, (Unaudited) In-process $ 3,048 $ 3,048 Total intangible assets, net $ 3,048 $ 3,048	Intangible asset consisted of the following (in thousands): As of 2020 2019 In-process $ 3,048 $ — Total intangible asset $ 3,048 $ —
Schedule of Other Non-current Assets	Other non-current As of June 30, December 31, (Unaudited) Capitalized transaction costs $ 8,496 $ 121 Operating right of use assets 3,219 1,486 Total other non-current $ 11,715 $ 1,607
Schedule of Accrued Expenses	Accrued expenses (in thousands): As of June 30, December 31, (Unaudited) Accrued bonus $ 2,926 $ 3,349 Accrued payroll and benefits 2,191 1,524 Accrued taxes 75 332 Accrued fabrication costs 2,304 2,321 Share appreciation rights 741 706 Other accrued expenses 3,867 2,163 Total accrued expenses $ 12,104 $ 10,395	Accrued expenses consist of the following (in thousands): As of 2020 2019 Accrued bonus $ 3,349 $ 2,501 Accrued payroll and benefits 1,524 602 Accrued taxes 332 75 Accrued fabrication costs 2,321 1,884 Share appreciation rights 706 435 Other accrued expenses 2,163 1,355 Total accrued expenses $ 10,395 $ 6,852

Long Term Debt (Tables)

Long Term Debt (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The following table summarizes information June 30, 2021 (Unaudited) Principal Fair Value Net 3.00% – 2020 Convertible Notes $ 21,281 $ 14,933 $ 36,214 8.00% – 2020 Convertible Notes 8,000 9,038 17,038 2020 Term Facility Loan 33,949 6,021 39,970 5.00% – $50.0 Million Convertible Notes 10,274 946 11,220 5.00% – $25.0 Million Convertible Notes 25,000 18,070 43,070 5.00% – $30.0 Million Convertible Notes 30,000 16,816 46,816 Total long-term debt $ 128,504 $ 65,824 $ 194,328 Less: current portion of long-term debt — — — Long-term debt, net of current portion $ 128,504 $ 65,824 $ 194,328 December 31, 2020 Principal Fair Value Net 3.00% – 2020 Convertible Notes $ 21,281 $ 10,825 $ 32,106 8.00% – 2020 Convertible Notes 8,000 6,789 14,789 2020 Term Facility Loan 22,500 2,549 25,049 Paycheck Protection Program 2,860 — 2,860 Total long-term debt $ 54,641 $ 20,163 $ 74,804 Less: current portion of long-term debt — — — Long-term debt, net of current portion $ 54,641 $ 20,163 $ 74,804	The following table summarizes information relating to our long-term debt, (in thousands): December 31, 2020 Principal Fair Value Net 3.0% – 2020 Convertible Notes $ 21,281 $ 10,825 $ 32,106 8.00% – 2020 Convertible Notes 8,000 6,789 14,789 2020 Term Facility Loan 22,500 2,549 25,049 Paycheck Protection Program 2,860 — 2,860 Total long-term debt $ 54,641 $ 20,163 $ 74,804 Less: current portion of long-term debt — — — Long-term debt, net of current portion $ 54,641 $ 20,163 $ 74,804
Schedule of Future Maturities of Debt Agreements	Future minimum payments under the debt agreements as of June 30, 2021 are as follows (in thousands): Convertible Notes 2021 (for the remaining period) $ — 2022 — 2023 — 2024 — 2025 114,179 Thereafter 50,274 Total future minimum payments $ 164,453 Less: current portion of debt principal — Non-current $ 164,453	Future minimum payments under the debt agreements as of December 31, 2020 are as follows (in thousands): Convertible Year Ending December 31: 2021 $ — 2022 — 2023 — 2024 — 2025 66,281 Thereafter 10,000 Total future minimum payments $ 76,281 Less: current portion of debt principal — Non-current $ 76,281

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]
Summary of Components of Provision for Income Tax	The components of provision for income tax for the years ended December 31, 2020 and 2019 are as follows (in thousands): Current Deferred Total Year ended December 31, 2020 U.K. operations $ — $ — $ — Foreign jurisdictions 569 — 569 $ 569 $ — $ 569 Current Deferred Total Year ended December 31, 2019 U.K. operations $ — $ — $ — Foreign jurisdictions 311 — 311 $ 311 $ — $ 311
Summary of Company's Deferred Taxes	The significant components of the Company’s deferred taxes are as follows (in thousands): December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 15,066 $ 7,494 Research and development credits — 1,217 Stock-based compensation 1,476 1,057 Lease liabilities 482 916 Accrued liabilities 788 633 Other 2 — Total gross deferred tax assets 17,814 11,317 Less valuation allowance (16,377 ) (9,520 ) Net deferred tax assets $ 1,437 $ 1,797 Deferred tax liabilities: Right-of-use $ (821 ) $ (1,064 ) Property and equipment, principally due to differences in depreciation (592 ) (733 ) Other (24 ) — Total gross deferred tax liabilities (1,437 ) (1,797 ) Net deferred tax assets $ — $ —
Summary of NOLs amd Tax Credit Gross Carryforwards	NOLs and tax credit gross carryforwards as of December 31, 2020 are as follows (in thousands): Amount Expiration Years NOLs, U.K. (gross) $ 79,293 See notes below Tax credits, Federal $ — See notes below Tax credits, State $ — See notes below
Summary of Unrecognized Tax Benefits	A reconciliation of the beginning and ending balances of unrecognized tax benefits is as follows (in thousands): Years Ended December 31, 2020 2019 Balance at beginning of the year $ 405 $ 271 Increases based on tax positions related to current year 733 134 Increases based on tax positions related to prior years 1,199 — Decreases based on tax positions related to prior years (101 ) — Balance at end of year $ 2,236 $ 405

Earnings per Share (Tables)

Earnings per Share (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share, Basic and Diluted	The following is a calculation of basic and diluted net loss per share (in thousands, except for share and per share amounts): Three Months Ended June 30 Six Months Ended June 30, 2021 2020 2021 2020 (Unaudited) (Unaudited) Basic and diluted Net loss $ (30,557 ) $ (10,003 ) $ (95,334 ) $ (26,429 ) Weighted average Ordinary Shares outstanding 33,922,973 33,625,899 33,850,070 33,554,441 Basic and diluted net loss per share $ (0.90 ) $ (0.30 ) $ (2.82 ) $ (0.79 )	A reconciliation of net loss available to ordinary shareholders and the number of shares in the calculation of basic and diluted net loss per share follows (in thousands, except for share and per share data): Years Ended December 31, 2020 2019 Basic and diluted: Net loss $ (80,277 ) $ (50,850 ) Weighted average Ordinary Shares outstanding 33,604,752 31,406,127 Basic and diluted net loss per share $ (2.39 ) $ (1.62 )
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share	For the three and six months ended June 30, 2021 and 2020, we excluded the potential effect of the following in the calculation of the diluted loss per share, as the effect would be anti-dilutive due to losses incurred: Three Months Ended Six Months Ended 2021 2020 2021 2020 (Unaudited) (Unaudited) Outstanding warrants, less outstanding warrants with a $0.01 exercise price $ 899,698 $ 842,717 $ 899,698 $ 842,717 Outstanding options (including performance options) $ 6,700,277 $ 6,412,668 $ 6,700,277 $ 6,412,668 $ 7,599,975 $ 7,255,385 $ 7,599,975 $ 7,255,385	As of December 31, 2020 and 2019, we excluded the potential effect of the following in the calculation of the diluted loss per share, as the effect would be anti-dilutive due to losses incurred. As of December 31, 2020 2019 Outstanding warrants, less 132,099 outstanding warrants with a $0.01 exercise price 881,004 848,240 Outstanding options 7,207,044 5,904,413 Outstanding performance awards 249,605 249,605 8,337,653 7,002,258

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	The following table summarizes the stock option activity related to the 2013 Share Option Plan: Number of Average Remaining Intrinsic (In thousands) Balances as of December 31, 2020 7,207,044 $ 4.94 6.75 $ 110,552 Options granted — $ — Options exercised (164,580 ) $ 1.72 Options forfeited (331,068 ) $ 10.30 Options expired (11,119 ) $ 6.66 Balances as of June 30, 2021 6,700,277 $ 4.75 6.16 $ 133,661 Options exercisable – June 30, 2021 $ 4,989,774 $ 3.56 5.31 $ 105,483	The following table summarizes stock option activity related to the plans during the years ended December 31, 2020 and 2019: Number of Average Remaining Intrinsic (Years) (In thousands) Balances as of December 31, 2018 5,565,292 $ 2.88 6.68 $ 59,146 Options granted 1,135,148 9.29 Options exercised (24,750 ) 1.33 Options forfeited (120,001 ) 6.65 Options expired (651,276 ) 2.78 Balances as of December 31, 2019 5,904,413 $ 4.05 6.94 $ 54,100 Options granted 2,328,385 8.67 Options exercised (7,813 ) 5.36 Options forfeited (826,488 ) 8.62 Options expired (191,453 ) 6.92 Balances as of December 31, 2020 7,207,044 $ 4.94 6.75 $ 110,552 Options exercisable—December 31, 2020 4,693,313 $ 3.16 5.51 $ 80,334
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense for all equity arrangements is included in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 (Unaudited) (Unaudited) Cost of revenue $ 363 $ 870 $ 631 $ 1,341 Research and development 1,171 1,330 2,219 2,081 Selling, general and administrative 442 345 851 767 Total stock-based compensation expense $ 1,976 $ 2,545 $ 3,701 $ 4,189	Stock-based compensation expense for all equity arrangements for the years ended December 31, 2020 and 2019 was as follows (in thousands): Years Ended December 31, 2020 2019 Cost of revenue $ 2,271 $ 2,230 Research and development 4,313 2,835 Sales and marketing 639 475 General and administrative 820 689 Total stock-based compensation expense $ 8,043 $ 6,229
Schedule of Fair Value Of Stock Options Valuation Assumptions And Methodology		The expecte d dividend rate is zero as the Company has not declared or paid any cash dividends and does not anticipate to do so in the foreseeable future. Years Ended December 31, 2020 2019 Expected term (in years) 4.86 – 6.25 5.61 Expected volatility (%) 50.29 – 52.45 50.40 – 51.37 Risk-free interest rate (%) 0.30 – 1.75 1.42 – 1.88 Fair value of Ordinary Shares $ 10.58 – 19.96 $ 13.21 – 13.52 Dividend yield — —
Summary of Warrant Information	The following table summarizes information related to our outstanding warrants. Investor Warrants in connection with the 8.00% – 2020 Convertible Notes and 5.00% – $25.0 Million Convertible Notes were excluded from the below table as they are classified as liabilities. Number of Weighted Weighted Balances as of December 31, 2020 1,013,103 $ 7.33 6.45 Warrants issued 18,694 $ 18.16 Warrants exercised (23,278 ) $ 0.00 Balances as of June 30, 2021 1,008,519 $ 7.70 5.78	The below warrants are equity classified and exercisable as of December 31, 2020 and 2019. Investor Warrants in connection with the 8.0% Convertible Notes were excluded from the below table as they were classified as liabilities. A summary of the Company’s outstanding warrants as of December 31, 2020 and 2019 are presented below Number of Weighted- Weighted- Balances as of December 31, 2018 678,232 $ 7.05 7.60 Warrants issued 304,864 7.44 Warrants exercised (2,757 ) 0.00 Warrants cancelled — — Balances as of December 31, 2019 980,339 $ 7.19 7.29 Warrants issued 51,859 10.30 Warrants exercised (5,523 ) 1.26 Warrants cancelled (13,572 ) 11.44 Balances as of December 31, 2020 1,013,103 $ 7.33 6.45

Leases (Tables)

Leases (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Summary of Operating Lease Information	The components of operating lease cost for the three and six months ended June 30, 2021 and 2020, were as follows (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 (Unaudited) (Unaudited) Operating Lease Cost: Fixed lease cost $ 292 $ 213 $ 505 $ 426 Variable lease cost 36 81 119 121 Total operating lease cost $ 328 $ 294 $ 624 $ 547 The supplemental cash flow information related to our operating leases is as follows (in thousands): Six Months Ended 2021 2020 Supplemental Cash Flow Information : Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 462 $ 454 Operating cash flows for finance leases $ — $ 12 Financing cash flows for finance leases $ — $ 933 Right-of-use Right-of-use $ 2,187 $ —	The components of lease cost for the year ended December 31, 2020, were as follows (in thousands): Years Ended December 31, 2020 2019 Operating Lease Cost: Fixed lease cost $ 851 777 Variable lease cost 154 253 Total operating cost $ 1,005 $ 1,030 Total lease cost $ 1,391 $ 1,533 Other information related to leases was as follows (in thousands): Years Ended December 31, 2020 2019 Supplemental Cash Flow Information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 916 $ 756 Operating cash flows for finance leases $ 15 $ 115 Financing cash flows for finance leases $ 1,192 $ 1,215 Right-of-use Right-of-use $ — $ 1,158
Schedule of Maturity of Operating Lease Liabilities	There are no finance lease liabilities as of June 30, 2021. Maturities of operating lease liabilities as of June 30, 2021, are as follows (in thousands): Operating Leases 2021 (for the remaining period) $ 582 2022 1,239 2023 931 2024 437 2025 327 Thereafter 394 Total lease obligation $ 3,910 Less: Imputed interest (408 ) Total lease liabilities $ 3,502 Less: Current lease liabilities (1,020 ) Total non-current $ 2,482	There are no finance lease liabilities as of December 31, 2020. Maturities of operating lease liabilities as of December 31, 2020, were as follows (in thousands): Operating Leases Year Ending December 31: 2021 $ 682 2022 613 2023 456 2024 121 Total lease obligation $ 1,872 Less: Imputed interest (149 ) Total lease liabilities $ 1,723 Less: Current lease liabilities (596 ) Total non-current $ 1,127

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	Non-cash Six Months Ended 2021 2020 (Unaudited) Supplemental Cash Flow Information: Interest pai d $ 271 $ 45 Income tax paid $ 210 $ 80 Non-cash Right-of-use $ 2,187 $ — $ 2,187 $ 0 Non-cash Unpaid property and equipment received $ 1,163 $ 295 Non-cash Unpaid deferred transaction cost s $ 5,201 $ — Forgiveness of Paycheck Protection Program loan $ (2,860 ) $ — $ 2,341 $ —	Non-cash Years Ended 2020 2019 Supplemental disclosure Cash payments for: Interest paid $ 47 $ 506 Income tax paid $ 313 $ 352 Schedule for noncash operating activities Right-of-use $ — $ 1,158 $ — $ 1,158 Schedule for noncash investing activities Unpaid property and equipment received $ 166 $ 397 Unpaid balance related to the Trutouch Asset Acquisition 500 — $ 666 $ 397 Schedule for noncash financing activities Conversion of note payable to Ordinary Shares $ — $ 18,244 Issuance of Ordinary Shares related to the Trutouch Asset Acquisition 2,298 — Non-cash — 995 Non-cash — 1,838 $ 2,298 $ 21,077

Description of Business and S_4

Description of Business and Significant Accounting Policies - Disclosure Of Useful Lives Of Property Plant And Equipment (Details)	12 Months Ended
	Dec. 31, 2020
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	4 years
Leaseholds and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Shorter of the lease term and the useful life

Description of Business and S_5

Description of Business and Significant Accounting Policies (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)Segment	Dec. 31, 2019USD ($)	Feb. 19, 2020
Business Acquisition [Line Items]
Accumulated deficit	$ 328,217,000		$ 232,883,000	$ 152,606,000
Net cash used in operating activities	54,457,000	$ 13,106,000	48,354,000	36,556,000
Cash and cash equivalents	$ 35,395,000		$ 19,228,000	20,904,000
Number of operating segments | Segment			1
Number of reportable segments | Segment			1
Impairment losses on equity method investments			$ 0	$ 0
Percentage of tax benefits to be realized for recognition in the income statement			50.00%	50.00%
8.00% Convertible Notes [Member] | Convertible Debt [Member]
Business Acquisition [Line Items]
Debt instrument, stated percentage	8.00%		8.00%		8.00%
Minimum [Member]
Business Acquisition [Line Items]
Credit period given to the customers			30 days
Maximum [Member]
Business Acquisition [Line Items]
Credit period given to the customers			45 days

Organization and Background Ad

Organization and Background Additional information (Detail) - Rockley Photonics Holdings Limited [Member] $ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)
Subsequent Event [Member] | The Business Combination [Member]
Business Acquisition [Line Items]
Cash Acquired in Excess of Payments to Acquire Business	$ 168
SC Health [Member]
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage	1.40%
Rockley Photonics Limited [Member]
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage	82.40%

Fiscal 2020 Asset Acquisition (

Fiscal 2020 Asset Acquisition (Details) - USD ($) $ / shares in Units, $ in Millions	Apr. 30, 2021	Nov. 25, 2020
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		$ 3.1
TruTouch Technologies, Inc. [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred		3.1
Payments to Acquire Businesses, Gross	$ 0.5	0.3
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		2.3
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	139,879
Shares Issued, Price Per Share	$ 16.43
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2.3
TruTouch Technologies, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross		$ 0.8

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Concentration Risk [Line Items]
Revenue	$ 2,195	$ 7,881	$ 3,966	$ 14,544	$ 22,343	$ 20,492
Revenue | Customer Concentration Risk | Customer A
Concentration Risk [Line Items]
Concentration risk	100.00%	69.00%	100.00%	83.00%	76.00%	67.00%
Revenue | Customer Concentration Risk | Customer B
Concentration Risk [Line Items]
Concentration risk	0.00%	31.00%	0.00%	17.00%	24.00%	33.00%
Accounts Receivable | Customer Concentration Risk | Customer A
Concentration Risk [Line Items]
Concentration risk			81.00%		33.00%	55.00%
Accounts Receivable | Customer Concentration Risk | Customer B
Concentration Risk [Line Items]
Concentration risk			17.00%		67.00%	45.00%
United States
Concentration Risk [Line Items]
Revenue	$ 2,195	$ 5,423	$ 3,966	$ 12,086	$ 17,037	$ 13,783
Rest of World
Concentration Risk [Line Items]
Revenue		$ 2,458		$ 2,458	$ 5,306	$ 6,709

Equity Method Investment (Detai

Equity Method Investment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Equity Method Investment
Beginning balance			$ 5,202	$ 1,486	$ 1,486
Investment in equity method investee				2,500	4,990
Share of loss of HRT	$ (597)	$ (102)	(760)	(252)	(1,274)	$ (1,281)
Ending balance	$ 4,711		$ 4,711		5,202	1,486
HRT | Variable Interest Entity
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage	24.90%		24.90%
Equity Method Investment
Beginning balance			$ 5,202	$ 1,486	1,486	2,767
Investment in equity method investee			0		4,990
Remeasurement gain on HRT			269
Share of loss of HRT			(760)		(1,274)	(1,281)
Ending balance	$ 4,711		$ 4,711		$ 5,202	$ 1,486

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2021	May 25, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 09, 2020	Feb. 19, 2020	Dec. 31, 2019
2017 Term Loan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
2017 Term Loan							$ 1,952
3.00% – 2020 Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	$ 36,200		$ 32,100
Debt instrument, stated percentage			3.00%
3.00% – 2020 Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	3.00%	3.00%	3.00%	3.00%	3.00%
Debt instrument, principal amount	$ 21,300		$ 21,300		$ 21,300
8.00% – 2020 Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	$ 17,000		$ 14,800
8.00% – 2020 Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	8.00%		8.00%			8.00%
Debt instrument, principal amount	$ 8,000		$ 8,000			$ 8,000
5.00% – $50.0 Million Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	$ 11,200
5.00% – $50.0 Million Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	5.00%
Debt instrument, principal amount	$ 50,000
5.00% – $25.0 Million Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	$ 43,100
5.00% – $25.0 Million Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	5.00%
Debt instrument, principal amount	$ 25,000
5.00% – $30.0 Million Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	$ 46,800
Debt instrument, stated percentage	5.00%
5.00% – $30.0 Million Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	5.00%
Debt instrument, principal amount	$ 30,000
Level 1 | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	11,316		11,516				12,343
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
2020 Term Facility Loan	39,970		25,049
Total financial liabilities	194,328		71,944				$ 1,952
Level 3 | 3.00% – 2020 Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	36,214		32,106
Level 3 | 8.00% – 2020 Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	17,038		$ 14,789
Level 3 | 5.00% – $50.0 Million Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	11,220
Level 3 | 5.00% – $25.0 Million Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	43,070
Level 3 | 5.00% – $30.0 Million Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	$ 46,816

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Significant Measurement Inputs (Details)	Jun. 30, 2021d	Dec. 31, 2020yrd
3.00% – 2020 Convertible Notes | Fair Value per share of ordinary shares | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		20.28
3.00% – 2020 Convertible Notes | Risk-free interest rate | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		0.10
3.00% – 2020 Convertible Notes | Risk-free interest rate | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		0.08
3.00% – 2020 Convertible Notes | Expected volatility | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		55
3.00% – 2020 Convertible Notes | Expected term, in years | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input | yr		4.19
3.00% – 2020 Convertible Notes | Expected term, in years | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input | yr		0.14
3.00% – 2020 Convertible Notes | Discount yield | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		48.4
3.00% – 2020 Convertible Notes | Conversion price discount | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		40
3.00% – 2020 Convertible Notes | Conversion price discount | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		25
8.00% – 2020 Convertible Notes | Fair Value per share of ordinary shares | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		20.28
8.00% – 2020 Convertible Notes | Risk-free interest rate | Level 3 | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		0.52
8.00% – 2020 Convertible Notes | Risk-free interest rate | Level 3 | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		0.08
8.00% – 2020 Convertible Notes | Expected volatility | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		55
8.00% – 2020 Convertible Notes | Expected term, in years | Level 3 | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input | yr		6.14
8.00% – 2020 Convertible Notes | Expected term, in years | Level 3 | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input | yr		0.14
8.00% – 2020 Convertible Notes | Discount yield | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		35
8.00% – 2020 Convertible Notes | Conversion price discount | Level 3 | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		40
8.00% – 2020 Convertible Notes | Conversion price discount | Level 3 | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		25
Convertible Notes | 3.00% – 2020 Convertible Notes | Fair Value per share of ordinary shares | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	24.70
Convertible Notes | 3.00% – 2020 Convertible Notes | Risk-free interest rate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.03
Convertible Notes | 3.00% – 2020 Convertible Notes | Expected volatility | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	55
Convertible Notes | 3.00% – 2020 Convertible Notes | Expected term, in years | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.10
Convertible Notes | 3.00% – 2020 Convertible Notes | Discount yield | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	48.45
Convertible Notes | 3.00% – 2020 Convertible Notes | Conversion price discount | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	25
Convertible Notes | 8.00% – 2020 Convertible Notes | Fair Value per share of ordinary shares | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	24.70
Convertible Notes | 8.00% – 2020 Convertible Notes | Risk-free interest rate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.03
Convertible Notes | 8.00% – 2020 Convertible Notes | Expected volatility | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	55
Convertible Notes | 8.00% – 2020 Convertible Notes | Expected term, in years | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.10
Convertible Notes | 8.00% – 2020 Convertible Notes | Discount yield | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	35
Convertible Notes | 8.00% – 2020 Convertible Notes | Conversion price discount | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	40
Convertible Notes | 5.00% – $50.0 Million Convertible Notes | Fair Value per share of ordinary shares | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	24.70
Convertible Notes | 5.00% – $50.0 Million Convertible Notes | Risk-free interest rate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.03
Convertible Notes | 5.00% – $50.0 Million Convertible Notes | Expected volatility | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	55
Convertible Notes | 5.00% – $50.0 Million Convertible Notes | Expected term, in years | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.10
Convertible Notes | 5.00% – $50.0 Million Convertible Notes | Discount yield | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	48.4
Convertible Notes | 5.00% – $25.0 Million Convertible Notes | Fair Value per share of ordinary shares | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	24.70
Convertible Notes | 5.00% – $25.0 Million Convertible Notes | Risk-free interest rate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.03
Convertible Notes | 5.00% – $25.0 Million Convertible Notes | Expected volatility | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	55
Convertible Notes | 5.00% – $25.0 Million Convertible Notes | Expected term, in years | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.10
Convertible Notes | 5.00% – $25.0 Million Convertible Notes | Discount yield | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	48.4
Convertible Notes | 5.00% – $30.0 Million Convertible Notes | Fair Value per share of ordinary shares | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	24.70
Convertible Notes | 5.00% – $30.0 Million Convertible Notes | Risk-free interest rate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.03
Convertible Notes | 5.00% – $30.0 Million Convertible Notes | Expected volatility | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	55
Convertible Notes | 5.00% – $30.0 Million Convertible Notes | Expected term, in years | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.10
Convertible Notes | 5.00% – $30.0 Million Convertible Notes | Discount yield | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	48.4
2020 Term Facility Loan | Fair Value per share of ordinary shares | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	24.70	20.28
2020 Term Facility Loan | Risk-free interest rate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.03	0.21
2020 Term Facility Loan | Expected volatility | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	55	55
2020 Term Facility Loan | Expected term, in years | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	0.10
2020 Term Facility Loan | Expected term, in years | Level 3 | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input | yr		4.13
2020 Term Facility Loan | Expected term, in years | Level 3 | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input | yr		0.14
2020 Term Facility Loan | Discount yield | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input	35
2020 Term Facility Loan | Conversion price discount | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, measurement input		35

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) $ in Thousands	3 Months Ended			6 Months Ended		10 Months Ended		12 Months Ended
	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)shares	May 25, 2021	Mar. 09, 2020USD ($)	Feb. 19, 2020USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt	$ 128,504	$ 54,641		$ 128,504		$ 54,641	$ 54,641	$ 54,641
Gain (loss) on debt instrument	(6,008)		$ 312	(45,661)	$ (2,222)			(20,163)	$ (2,969)
2020 Term Facility Loan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, principal amount	35,000	35,000		35,000		35,000	35,000	35,000
Long-term debt	33,949	22,500		33,949		22,500	22,500	22,500
Convertible notes	40,000	25,100		40,000		$ 25,100	$ 25,100	25,100
Gain (loss) on debt instrument	1,200	$ 1,729		14,921				$ 1,700
Percentage of principal In addition to unpaid interest Will be converted upon qualified financing								280
2019 Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, principal amount									$ 15,000
Debt Conversion, Converted Instrument, Shares Issued | shares									1,336,344
3.00% – 2020 Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage		3.00%				3.00%	3.00%	3.00%
Long-term debt		$ 21,281				$ 21,281	$ 21,281	$ 21,281
Convertible notes	$ 36,200	$ 32,100		$ 36,200		$ 32,100	32,100	$ 32,100
Gain (loss) on debt instrument							$ 10,825
3.00% – 2020 Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%		3.00%	3.00%
Debt instrument, principal amount	$ 21,300	$ 21,300		$ 21,300		$ 21,300	$ 21,300	$ 21,300			$ 21,300
Long-term debt	21,281	21,281		21,281		21,281	21,281	21,281
Gain (loss) on debt instrument	1,100			4,108				10,800
8.00% – 2020 Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt		8,000				8,000	8,000	8,000
Convertible notes	$ 17,000	$ 14,800		$ 17,000		14,800	$ 14,800	$ 14,800
Gain (loss) on debt instrument						$ 4,374
8.00% – 2020 Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	8.00%	8.00%		8.00%		8.00%	8.00%	8.00%				8.00%
Debt instrument, principal amount	$ 8,000	$ 8,000		$ 8,000		$ 8,000	$ 8,000	$ 8,000				$ 8,000
Long-term debt	8,000	$ 8,000		8,000		$ 8,000	$ 8,000	8,000
Gain (loss) on debt instrument	500			2,249				$ 6,800
5.00% – $50.0 Million Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	$ 11,200			$ 11,200
5.00% – $50.0 Million Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	5.00%			5.00%
Debt instrument, principal amount	$ 50,000			$ 50,000
Long-term debt	10,274			10,274
Gain (loss) on debt instrument	300			946
5.00% – $25.0 Million Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes	$ 43,100			$ 43,100
5.00% – $25.0 Million Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	5.00%			5.00%
Debt instrument, principal amount	$ 25,000			$ 25,000
Long-term debt	25,000			25,000
Gain (loss) on debt instrument	1,300			5,478
Debt instrument, convertible, denominator used to calculate conversion price at maturity date, amount	$ 675,000			$ 675,000
5.00% – $30.0 Million Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	5.00%			5.00%
Convertible notes	$ 46,800			$ 46,800
5.00% – $30.0 Million Convertible Notes | Convertible Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, stated percentage	5.00%			5.00%
Debt instrument, principal amount	$ 30,000			$ 30,000
Long-term debt	30,000			30,000
Gain (loss) on debt instrument	1,400			8,413
Debt instrument, convertible, denominator used to calculate conversion price at maturity date, amount	$ 800,000			$ 800,000

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Rollforward (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended		10 Months Ended		12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Plus: Loss from change in fair value	$ (6,008)		$ 312	$ (45,661)	$ (2,222)			$ (20,163)	$ (2,969)
2020 Term Facility Loan
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		$ 23,320		25,049
Plus: Loss from change in fair value	1,200	1,729		14,921				1,700
Ending balance	39,970	25,049		39,970		$ 25,049	$ 25,049	25,049
3.00% – 2020 Convertible Notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance				32,106		21,281
Plus: Loss from change in fair value						10,825
Ending balance		32,106				32,106	32,106	32,106
3.00% – 2020 Convertible Notes | Convertible Notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance				32,106
Plus: Loss from change in fair value	1,100			4,108				10,800
Ending balance	36,214	32,106		36,214		32,106	32,106	32,106
8.00% – 2020 Convertible Notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance				14,789			10,415
Plus: Loss from change in fair value							4,374
Ending balance		14,789				14,789	14,789	14,789
8.00% – 2020 Convertible Notes | Convertible Notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance				14,789
Plus: Loss from change in fair value	500			2,249				6,800
Ending balance	17,038	14,789		17,038		14,789	14,789	14,789
5.00% – $50.0 Million Convertible Notes | Convertible Notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance				10,274
Plus: Loss from change in fair value	300			946
Ending balance	11,220	10,274		11,220		10,274	10,274	10,274
5.00% – $25.0 Million Convertible Notes | Convertible Notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance				37,592
Plus: Loss from change in fair value	1,300			5,478
Ending balance	43,070	37,592		43,070		37,592	37,592	37,592
5.00% – $30.0 Million Convertible Notes | Convertible Notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance				38,403
Plus: Loss from change in fair value	1,400			8,413
Ending balance	$ 46,816	$ 38,403		$ 46,816		$ 38,403	$ 38,403	$ 38,403

Balance Sheet Components - Cash

Balance Sheet Components - Cash and Cash Equivalents (Details) - Cash and Cash Equivalents - Geographic Concentration Risk	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
United Kingdom
Cash and Cash Equivalents [Line Items]
Concentration risk	92.00%	96.00%	95.00%
United States
Cash and Cash Equivalents [Line Items]
Concentration risk	7.00%	3.00%	4.00%
Other
Cash and Cash Equivalents [Line Items]
Concentration risk	1.00%	1.00%	1.00%

Balance Sheet Components - Othe

Balance Sheet Components - Other Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
R&D tax credit receivable	$ 21,911	$ 17,412	$ 14,731
Grants receivable	573	0	239
VAT receivable	549	607	886
Other receivables	4	5	93
Total other receivables	$ 23,037	$ 18,024	$ 15,949

Balance Sheet Components - Long

Balance Sheet Components - Long Lived Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 13,386		$ 13,386		$ 9,852	$ 8,221
Less: accumulated depreciation	(7,162)		(7,162)		(5,802)	(3,561)
Total property and equipment, net	6,224		6,224		4,050	4,660
Depreciation	1,000	$ 600	1,800	$ 1,200	2,400	1,500
Finance lease right-of-use assets	2,966		2,966		2,966	3,105
Less: accumulated amortization	(1,020)		(1,020)		(834)	(485)
Total finance lease right-of-use assets, net	1,946		1,946		2,132	2,620
Amortization	100	$ 100	200	$ 200	400	400
Computer equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	1,744		1,744		1,218	1,020
Lab equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	10,081		10,081		7,607	5,614
Motor vehicles
Property, Plant and Equipment [Line Items]
Total property and equipment	31		31		31	31
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment	265		265		265	265
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	704		704		704	704
Assets under construction
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 561		$ 561		$ 27	$ 587

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Indefinite-lived Intangible Assets [Line Items]
Intangible assets, net	$ 3,048	$ 3,048	$ 0
In-process research and development
Indefinite-lived Intangible Assets [Line Items]
Intangible assets, net	$ 3,048	$ 3,048	$ 0

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Other Non-current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Capitalized transaction costs	$ 8,496	$ 121
Operating right of use assets	3,219	1,486
Other non-current assets	$ 11,715	$ 1,607	$ 2,212

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued bonus	$ 2,926	$ 3,349	$ 2,501
Accrued payroll and benefits	2,191	1,524	602
Accrued taxes	75	332	75
Accrued fabrication costs	2,304	2,321	1,884
Share appreciation rights	741	706	435
Other accrued expenses	3,867	2,163	1,355
Accrued expenses	$ 12,104	$ 10,395	$ 6,852

Long Term Debt - Summary of Lon

Long Term Debt - Summary of Long Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2021	May 25, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 09, 2020	Feb. 19, 2020	Dec. 31, 2019
Principal
Total long-term debt	$ 128,504		$ 54,641
Less: current portion of long-term debt	0		0				$ (1,952)
Non-current portion of debt principal	128,504		54,641
Fair Value Adjustment
Total long-term debt	65,824		20,163
Less: current portion of long-term debt	0		0
Long-term debt, net of current portion	65,824		20,163
Net
Total long-term debt	194,328		74,804
Less: current portion of long-term debt	0		0
Long-term debt	$ 194,328		$ 74,804				$ 0
3.00% – 2020 Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage			3.00%
Principal
Total long-term debt			$ 21,281
Fair Value Adjustment
Total long-term debt			10,825
Net
Total long-term debt			32,106
8.00% – 2020 Convertible Notes
Principal
Total long-term debt			8,000
Fair Value Adjustment
Total long-term debt			6,789
Net
Total long-term debt			14,789
5.00% – $30.0 Million Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage	5.00%
Convertible Notes
Principal
Less: current portion of long-term debt	$ 0		0
Non-current portion of debt principal	$ 164,453		$ 76,281
Convertible Notes | 3.00% – 2020 Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage	3.00%	3.00%	3.00%	3.00%	3.00%
Debt instrument, principal amount	$ 21,300		$ 21,300		$ 21,300
Principal
Total long-term debt	21,281		21,281
Fair Value Adjustment
Total long-term debt	14,933		10,825
Net
Total long-term debt	$ 36,214		$ 32,106
Convertible Notes | 8.00% – 2020 Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage	8.00%		8.00%			8.00%
Debt instrument, principal amount	$ 8,000		$ 8,000			$ 8,000
Principal
Total long-term debt	8,000		8,000
Fair Value Adjustment
Total long-term debt	9,038		6,789
Net
Total long-term debt	$ 17,038		14,789
Convertible Notes | 5.00% – $50.0 Million Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage	5.00%
Debt instrument, principal amount	$ 50,000
Principal
Total long-term debt	10,274
Fair Value Adjustment
Total long-term debt	946
Net
Total long-term debt	$ 11,220
Convertible Notes | 5.00% – $25.0 Million Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage	5.00%
Debt instrument, principal amount	$ 25,000
Principal
Total long-term debt	25,000
Fair Value Adjustment
Total long-term debt	18,070
Net
Total long-term debt	$ 43,070
Convertible Notes | 5.00% – $30.0 Million Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage	5.00%
Debt instrument, principal amount	$ 30,000
Principal
Total long-term debt	30,000
Fair Value Adjustment
Total long-term debt	16,816
Net
Total long-term debt	46,816
2020 Term Facility Loan
Debt Instrument [Line Items]
Debt instrument, principal amount	35,000		35,000
Principal
Total long-term debt	33,949		22,500
Fair Value Adjustment
Total long-term debt	6,021		2,549
Net
Total long-term debt	$ 39,970		25,049
Paycheck Protection Program
Principal
Total long-term debt			2,860
Non-current portion of debt principal			2,900
Fair Value Adjustment
Total long-term debt			0
Net
Total long-term debt			$ 2,860

Long Term Debt - Schedule of Fu

Long Term Debt - Schedule of Future Minimum Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Less: current portion of long-term debt	$ 0	$ 0	$ (1,952)
Non-current portion of debt principal	128,504	54,641
Convertible Notes
Debt Instrument [Line Items]
2021 (for the remaining period)	0	0
2022	0	0
2023	0	0
2024	0	0
2025	114,179	66,281
Thereafter	50,274	10,000
Long-term debt, net of current portion	164,453	76,281
Less: current portion of long-term debt	0	0
Non-current portion of debt principal	$ 164,453	$ 76,281

Long Term Debt - Narrative (Det

Long Term Debt - Narrative (Details)	Dec. 31, 2020USD ($)$ / sharesshares	Apr. 21, 2020USD ($)	Jun. 12, 2019USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / shares	Jun. 12, 2019USD ($)$ / shares	Jun. 30, 2021USD ($)$ / shares	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)$ / shares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Dec. 31, 2017$ / shares	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2017$ / shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	May 25, 2021	Oct. 20, 2020USD ($)$ / shares	Sep. 29, 2020USD ($)	Mar. 09, 2020USD ($)	Feb. 19, 2020USD ($)$ / shares	Mar. 31, 2019USD ($)	Mar. 27, 2019USD ($)	Mar. 05, 2019USD ($)	May 26, 2017USD ($)	Jan. 27, 2017USD ($)
Debt Instrument [Line Items]
Gain (loss) on debt instrument						$ (6,008,000)			$ 312,000	$ (45,661,000)	$ (2,222,000)					$ (20,163,000)	$ (2,969,000)
Long-term debt	$ 54,641,000			$ 128,504,000		$ 128,504,000		$ 54,641,000		$ 128,504,000			$ 54,641,000	$ 54,641,000		$ 54,641,000
Warrants issued (in shares) | shares										18,694						51,859	304,864
Warrants outstanding, exercise price (in dollars per share) | $ / shares	$ 0.01			$ 0.01		$ 0.01		$ 0.01		$ 0.01			$ 0.01	$ 0.01		$ 0.01	$ 0.01
Forgiveness of Paycheck Protection Program loan				$ 2,900,000		$ 2,860,000				$ 2,860,000	0
Class of warrants or rights exercise price | $ / shares	$ 0.01			$ 0.01		$ 0.01		$ 0.01		$ 0.01			$ 0.01	$ 0.01		$ 0.01	$ 0.01
Proceeds from the issuance of common stock											1,961,000					$ 1,961,000	$ 38,639,000
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings						$ (6,008,000)			$ 312,000	$ (45,661,000)	$ (2,222,000)					(20,163,000)	$ (2,969,000)
Long term debt net of current portion	$ 54,641,000			$ 128,504,000		$ 128,504,000		$ 54,641,000		$ 128,504,000			$ 54,641,000	$ 54,641,000		$ 54,641,000
3.00% – 2020 Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage	3.00%							3.00%					3.00%	3.00%		3.00%
Gain (loss) on debt instrument														$ 10,825,000
Long-term debt	$ 21,281,000							$ 21,281,000					$ 21,281,000	21,281,000		$ 21,281,000
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings														10,825,000
8.00% – 2020 Convertible Notes
Debt Instrument [Line Items]
Gain (loss) on debt instrument													4,374,000
Long-term debt	8,000,000							8,000,000					8,000,000	8,000,000		8,000,000
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings													4,374,000
5.00% – $30.0 Million Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage				5.00%		5.00%				5.00%
Convertible Notes
Debt Instrument [Line Items]
Long term debt net of current portion	$ 76,281,000			$ 164,453,000		$ 164,453,000		$ 76,281,000		$ 164,453,000			$ 76,281,000	$ 76,281,000		$ 76,281,000
Convertible Notes | 3.00% – 2020 Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage	3.00%			3.00%		3.00%		3.00%	3.00%	3.00%	3.00%		3.00%	3.00%		3.00%			3.00%			3.00%
Unpaid interest						$ 100,000				$ 300,000
Gain (loss) on debt instrument						1,100,000				4,108,000						$ 10,800,000
Long-term debt	$ 21,281,000			$ 21,281,000		21,281,000		$ 21,281,000		21,281,000			$ 21,281,000	$ 21,281,000		21,281,000
Debt instrument, principal amount	21,300,000			21,300,000		21,300,000		21,300,000		21,300,000			21,300,000	21,300,000		21,300,000						$ 21,300,000
Long term debt term																						5 years
Debt instrument face value	$ 21,300,000			$ 21,300,000		21,300,000		$ 21,300,000		21,300,000			$ 21,300,000	$ 21,300,000		21,300,000						$ 21,300,000
Proceeds from the issuance of common stock																300,000
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings						$ 1,100,000				$ 4,108,000						10,800,000
Convertible Notes | 3.00% – 2020 Convertible Notes | Prospective Equity Financing [Member]
Debt Instrument [Line Items]
Proceeds from the issuance of common stock																$ 10,000,000
Debt instrument conversion price price per share | $ / shares																				$ 14.298
Convertible Notes | 3.00% – 2020 Convertible Notes | Prospective Exit Event [Member]
Debt Instrument [Line Items]
Debt instrument conversion price price per share | $ / shares																				14.298
Convertible Notes | 3.00% – 2020 Convertible Notes | Maturity [Member]
Debt Instrument [Line Items]
Debt instrument conversion price price per share | $ / shares																				14.298
Convertible Notes | 3.00% – 2020 Convertible Notes | If Equity Financing Is Not Raised [Member]
Debt Instrument [Line Items]
Debt instrument conversion price price per share | $ / shares																				$ 14.298
Convertible Notes | 3.00% – 2020 Convertible Notes | Tranche One [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount																						20,000,000
Debt instrument face value																						$ 20,000,000
Convertible Notes | 3.00% – 2020 Convertible Notes | Tranche Two [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount																				$ 1,300,000
Debt instrument face value																				$ 1,300,000
Convertible Notes | 8.00% – 2020 Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage	8.00%			8.00%		8.00%		8.00%		8.00%			8.00%	8.00%		8.00%							8.00%
Unpaid interest						$ 200,000			$ 100,000	$ 300,000	$ 200,000
Gain (loss) on debt instrument						500,000				2,249,000						$ 6,800,000
Long-term debt	$ 8,000,000			$ 8,000,000		8,000,000		$ 8,000,000		8,000,000			$ 8,000,000	$ 8,000,000		8,000,000
Debt instrument, principal amount	8,000,000			8,000,000		8,000,000		8,000,000		8,000,000			8,000,000	8,000,000		8,000,000							$ 8,000,000
Long term debt term																							7 years
Debt instrument face value	$ 8,000,000			$ 8,000,000		8,000,000		8,000,000		8,000,000			8,000,000	8,000,000		8,000,000							$ 8,000,000
Proceeds from the issuance of common stock																600,000
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings						$ 500,000				$ 2,249,000						6,800,000
Convertible Notes | 8.00% – 2020 Convertible Notes | Investor Warrants Exercisable Into Common Stock [Member]
Debt Instrument [Line Items]
Warrants outstanding, exercise price (in dollars per share) | $ / shares																							$ 0.00001
Class of warrants or rights exercise price | $ / shares																							0.00001
Convertible Notes | 8.00% – 2020 Convertible Notes | Prospective Equity Financing [Member]
Debt Instrument [Line Items]
Debt instrument conversion price price per share | $ / shares																							$ 14.298
Convertible Notes | 8.00% – 2020 Convertible Notes | Prospective Exit Event [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price, discount																							25.00%
Shares issued price per share | $ / shares																							$ 14.298
Convertible Notes | 8.00% – 2020 Convertible Notes | Maturity [Member]
Debt Instrument [Line Items]
Debt instrument conversion price price per share | $ / shares																							$ 14.298
Convertible Notes | 5.00% – $50.0 Million Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage				5.00%		5.00%				5.00%
Unpaid interest						$ 100,000				$ 300,000
Gain (loss) on debt instrument						300,000				946,000
Long-term debt				$ 10,274,000		10,274,000				10,274,000
Debt instrument, principal amount				50,000,000		50,000,000				50,000,000
Proceeds from equity triggering debt conversion, minimum, amount				$ 25,000,000		$ 25,000,000				$ 25,000,000
Debt instrument, convertible, conversion price, discount				15.00%		15.00%				15.00%
Debt instrument, convertible, denominator used to calculate conversion price, amount				$ 1,500,000,000		$ 1,500,000,000				$ 1,500,000,000
Debt instrument face value				$ 50,000,000		50,000,000				50,000,000
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings						$ 300,000				$ 946,000
Convertible Notes | 5.00% – $25.0 Million Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage				5.00%		5.00%				5.00%
Unpaid interest						$ 300,000				$ 600,000
Gain (loss) on debt instrument						1,300,000				5,478,000
Long-term debt				$ 25,000,000		25,000,000				25,000,000
Debt instrument, principal amount				25,000,000		25,000,000				25,000,000
Proceeds from equity triggering debt conversion, minimum, amount				$ 25,000,000		$ 25,000,000				$ 25,000,000
Debt instrument, convertible, conversion price, discount				25.00%		25.00%				25.00%
Debt instrument, convertible, denominator used to calculate conversion price, amount				$ 800,000,000		$ 800,000,000				$ 800,000,000
Debt instrument, convertible, denominator used to calculate conversion price at maturity date, amount				$ 675,000,000		$ 675,000,000				$ 675,000,000
Debt instrument, conversion price										100.00%
Warrants issued (in shares) | shares	278,775
Warrants outstanding, stated rate				5.00%		5.00%				5.00%
Warrants outstanding, exercise price (in dollars per share) | $ / shares				$ 0.00001		$ 0.00001				$ 0.00001
Debt instrument face value				$ 25,000,000		$ 25,000,000				$ 25,000,000
Class of warrants or rights exercise price | $ / shares				$ 0.00001		$ 0.00001				$ 0.00001
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings						$ 1,300,000				$ 5,478,000
Convertible Notes | 5.00% – $30.0 Million Convertible Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage				5.00%		5.00%				5.00%
Unpaid interest						$ 400,000				$ 700,000
Gain (loss) on debt instrument						1,400,000				8,413,000
Long-term debt				$ 30,000,000		30,000,000				30,000,000
Debt instrument, principal amount				30,000,000		30,000,000				30,000,000
Proceeds from equity triggering debt conversion, minimum, amount				$ 25,000,000		$ 25,000,000				$ 25,000,000
Debt instrument, convertible, conversion price, discount				25.00%		25.00%				25.00%
Debt instrument, convertible, denominator used to calculate conversion price, amount				$ 800,000,000		$ 800,000,000				$ 800,000,000
Debt instrument, convertible, denominator used to calculate conversion price at maturity date, amount				800,000,000		800,000,000				800,000,000
Debt instrument face value				30,000,000		30,000,000				30,000,000
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings						1,400,000				8,413,000
Convertible Notes | Two Thousand And Nineteen Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount																								$ 15,000,000
Long term debt term																	2 years
Debt instrument face value																								$ 15,000,000
Long term debt fixed rate percentage																	8.00%
Convertible Notes | Two Thousand And Nineteen Convertible Notes [Member] | Equity Financing [Member]
Debt Instrument [Line Items]
Proceeds from the issuance of common stock			$ 24,000,000
Debt instrument conversion price price per share | $ / shares			$ 11.44		$ 11.44
Interest Expense, Debt, Excluding Amortization					$ 300,000												$ 15,000,000
Debt Conversion, Converted Instrument, Shares Issued | shares			1,336,344
Gain (Loss) on Extinguishment of Debt																	$ 3,000,000
Share Price | $ / shares			$ 13.65		$ 13.65
Convertible Notes | Two Thousand And Nineteen Convertible Notes [Member] | Forecast [Member] | Prospective Equity Financing [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price, discount																	20.00%
Proceeds from the issuance of common stock																	$ 10,000,000
Debt instrument conversion price price per share | $ / shares																	$ 11.4384
Shares issued price per share | $ / shares																	14.298
Convertible Notes | Two Thousand And Nineteen Convertible Notes [Member] | Forecast [Member] | Prospective Exit Event [Member]
Debt Instrument [Line Items]
Debt instrument conversion price price per share | $ / shares																	14.298
Convertible Notes | Two Thousand And Nineteen Convertible Notes [Member] | Forecast [Member] | Maturity [Member]
Debt Instrument [Line Items]
Debt instrument conversion price price per share | $ / shares																	$ 14.298
Convertible Notes | Two Thousand And Nineteen Convertible Notes [Member] | Tranche One [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount																										$ 6,700,000
Debt instrument face value																										$ 6,700,000
Convertible Notes | Two Thousand And Nineteen Convertible Notes [Member] | Tranche Two [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount																									$ 8,300,000
Debt instrument face value																									$ 8,300,000
2020 Term Facility Loan
Debt Instrument [Line Items]
Gain (loss) on debt instrument						1,200,000		1,729,000		14,921,000						1,700,000
Interest paid						200,000				300,000
Long-term debt	$ 22,500,000			33,949,000		33,949,000		22,500,000		33,949,000			22,500,000	22,500,000		22,500,000
Debt instrument, portion to be converted to equity																			30.00%
Debt instrument, portion to be repaid																			70.00%
Debt instrument, principal amount	35,000,000			35,000,000		35,000,000		35,000,000		35,000,000			35,000,000	35,000,000		35,000,000
Debt instrument face value	35,000,000			$ 35,000,000		35,000,000		35,000,000		35,000,000			35,000,000	35,000,000		35,000,000
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings						$ 1,200,000		1,729,000		14,921,000						1,700,000
2020 Term Facility Loan
Debt Instrument [Line Items]
Gain (loss) on debt instrument							$ 1,200,000			14,900,000
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings							$ 1,200,000			$ 14,900,000
January Two Thousand And Seventeen Term Loan [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount																												$ 5,000,000
Warrants outstanding, exercise price (in dollars per share) | $ / shares												$ 8.646			$ 8.646			$ 8.646
Long term debt date of maturity												Mar. 31, 2020			Mar. 31, 2020			Mar. 31, 2020
Long term debt term												36 months			36 months			36 months
Long term debt floor rate												9.00%			9.00%			9.00%
Debt instrument face value																												$ 5,000,000
Class of warrants or rights warrants issued during the period units | shares																		52,050
Class of warrants or rights exercise price | $ / shares												$ 8.646			$ 8.646			$ 8.646
Class of warrants or rights maturity date												Jan. 27, 2027			Jan. 27, 2027			Jan. 27, 2027
January Two Thousand And Seventeen Term Loan [Member] | Prime Rate [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate spread															5.50%
May Two Thousand And Seventeen Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount																											$ 10,000,000
Long term debt term												36 months			36 months			36 months
Debt instrument variable interest rate spread												5.50%
Long term debt floor rate												9.00%			9.00%			9.00%
Debt instrument face value																											10,000,000
Long term debt variable interest rate percentage																	11.00%
Proceeds from long term bank loan																		$ 5,000,000
May Two Thousand And Seventeen Term Loan [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount																											5,000,000
Debt instrument face value																											5,000,000
May Two Thousand And Seventeen Term Loan [Member] | Kreos Capital [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount																											4,500,000
Warrants outstanding, exercise price (in dollars per share) | $ / shares												$ 8.646			$ 8.646			$ 8.646
Debt instrument face value																											$ 4,500,000
Class of warrants or rights warrants issued during the period units | shares																		52,050
Class of warrants or rights exercise price | $ / shares												$ 8.646			$ 8.646			$ 8.646
Class of warrants or rights maturity date												May 26, 2027			May 26, 2027			May 26, 2027
Term Loan [Member] | Two Thousand And Nineteen Convertible Notes [Member]
Debt Instrument [Line Items]
Gain (loss) on debt instrument																2,500,000
Interest paid																2
Long-term debt	$ 22,500,000							$ 22,500,000					$ 22,500,000	$ 22,500,000		$ 22,500,000
Debt instrument, principal amount																					$ 35,000,000
Debt instrument face value																					$ 35,000,000
Long term debt fixed rate percentage	0.10%							0.10%					0.10%	0.10%		0.10%
Fair value measurements with unobservable inputs reconciliation recurring basis liability gain loss included in earnings																$ 2,500,000
Term Loan [Member] | Two Thousand And Nineteen Convertible Notes [Member] | Prospective Qualified Exit [Member] | Minimum [Member]
Debt Instrument [Line Items]
Public float	$ 350,000,000							$ 350,000,000					$ 350,000,000	$ 350,000,000		350,000,000
Paycheck Protection Program, CARES Act [Member]
Debt Instrument [Line Items]
Long-term debt	$ 2,860,000							$ 2,860,000					$ 2,860,000	$ 2,860,000		$ 2,860,000
Long term debt term	24 months							24 months					24 months	24 months		24 months
Proceeds from long term bank loan		$ 2,900,000
Long term debt fixed rate percentage	1.00%							1.00%					1.00%	1.00%		1.00%
Number of times the payroll expenses for which the loan may be borrowed		2.5
Long term debt net of current portion	$ 2,900,000							$ 2,900,000					$ 2,900,000	$ 2,900,000		$ 2,900,000

Income Taxes - Summary of Loss

Income Taxes - Summary of Loss Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]
U.K. Operations	$ (82,705)	$ (53,291)
Foreign operations	2,997	2,752
Loss before income taxes	$ (79,708)	$ (50,539)

Income Taxes - Summary of Compo

Income Taxes - Summary of Components of Provision for Income Tax (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Current
U.K. operations					$ 0	$ 0
Foreign jurisdictions					569	311
Current income tax expense					569	311
Deferred
U.K. operations					0	0
Foreign jurisdictions					0	0
Deferred income tax expense					0	0
Total
U.K. operations					0	0
Foreign jurisdictions					569	311
Total	$ 110	$ 80	$ 210	$ 220	$ 569	$ 311

Income Taxes - Summary of Effec

Income Taxes - Summary of Effective Tax Rate of the Company's Provision for Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
U.K. Statutory Rate					$ (15,145)	$ (9,602)
Foreign income tax					308	96
Research & Development credit					(628)	(1,086)
Stock-based compensation					1,293	758
Permanent differences					3,325	(681)
Change in valuation allowance					7,480	2,636
Losses not benefited					3,999	8,169
Others, net					(63)	21
Total	$ 110	$ 80	$ 210	$ 220	$ 569	$ 311
U.K. Statutory Rate					19.00%	19.00%
Foreign income tax					(0.40%)	(0.20%)
Research & Development credit					0.80%	2.10%
Stock-based compensation					(1.60%)	(1.50%)
Permanent differences					(4.20%)	1.30%
Change in valuation allowance					(9.40%)	(5.20%)
Losses not benefited					(5.00%)	(16.10%)
Others, net					0.10%	0.00%
Total			1.00%		(0.70%)	(0.60%)

Income Taxes - Summary of Compa

Income Taxes - Summary of Company's Deferred Taxes (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 15,066	$ 7,494
Research and development credits	0	1,217
Stock-based compensation	1,476	1,057
Lease liabilities	482	916
Accrued liabilities	788	633
Other	2	0
Total gross deferred tax assets	17,814	11,317
Less valuation allowance	(16,377)	(9,520)
Net deferred tax assets	1,437	1,797
Deferred tax liabilities:
Right-of-use Assets	(821)	(1,064)
Property and equipment, principally due to differences in depreciation	(592)	(733)
Other	(24)	0
Total gross deferred tax liabilities	(1,437)	(1,797)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Summary of Com_2

Income Taxes - Summary of Company's Deferred Taxes (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Valuation allowance deferred tax assets increase decrease amount	$ 6.9	$ 2.8

Income Taxes - Summary of NOLs

Income Taxes - Summary of NOLs amd Tax Credit Gross Carryforwards (Detail) $ in Thousands	Dec. 31, 2020USD ($)
Domestic Tax Authority [Member]
Summary Of Net Operating Losses And Tax Credit Losses Carried Forward [Line Items]
Tax credits	$ 0
State and Local Jurisdiction [Member]
Summary Of Net Operating Losses And Tax Credit Losses Carried Forward [Line Items]
Tax credits	0
Indefinitely Carried Forward [Member] | Domestic Tax Authority [Member]
Summary Of Net Operating Losses And Tax Credit Losses Carried Forward [Line Items]
NOLs, U.K. (gross)	$ 79,293

Income Taxes - Summary of NOL_2

Income Taxes - Summary of NOLs amd Tax Credit Gross Carryforwards (Parenthetical) (Detail) $ in Thousands	Dec. 31, 2020USD ($)
Domestic Tax Authority [Member] | Indefinitely Carried Forward [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards	$ 79,293

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Contingency [Line Items]
Provision for income tax	$ 110	$ 80	$ 210	$ 220	$ 569	$ 311
Effective income tax rate, percent (less than)			1.00%		(0.70%)	(0.60%)
Unrecognized tax benefits beginning balance					$ 2,236	$ 405	$ 271
Domestic Tax Authority [Member] | Tax Year 2018 [Member]
Income Tax Contingency [Line Items]
Open tax year							2018

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Balance at beginning of the year	$ 405	$ 271
Increases based on tax positions related to current year	733	134
Increases based on tax positions related to prior years	1,199	0
Decreases based on tax positions related to prior years	(101)
Balance at end of year	$ 2,236	$ 405

Ordinary Shares (Details)

Ordinary Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2021	Mar. 11, 2021	Dec. 31, 2020	Dec. 31, 2019
Ordinary shares, par value (in dollars per share)			$ 0.00001	$ 0.00001
Rockley Photonics Holdings Limited
Ordinary shares, par value (in dollars per share)		$ 0.00001
Additional paid in capital	$ 50	$ 50
Rockley Photonics Holdings Limited | Management [Member]
Additional paid in capital		$ 50,000

Earnings per Share - Net Loss A

Earnings per Share - Net Loss Available to Ordinary Shareholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Net loss, basic	$ (30,557)	$ (10,003)	$ (95,334)	$ (26,429)	$ (80,277)	$ (50,850)
Net loss, diluted	$ (30,557)	$ (10,003)	$ (95,334)	$ (26,429)	$ (80,277)	$ (50,850)
Weighted-average shares outstanding, basic (in shares)	33,922,973	33,625,899	33,850,070	33,554,441	33,604,752	31,406,127
Weighted-average shares outstanding, diluted (in shares)	33,922,973	33,625,899	33,850,070	33,554,441	33,604,752	31,406,127
Net loss per share, basic (in dollars per share)	$ (0.90)	$ (0.30)	$ (2.82)	$ (0.79)	$ (2.39)	$ (1.62)
Net loss per share, diluted (in dollars per share)	$ (0.90)	$ (0.30)	$ (2.82)	$ (0.79)	$ (2.39)	$ (1.62)

Earnings per Share - Summary of

Earnings per Share - Summary of Anti-dilutive Securities (Details) - $ / shares	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrants outstanding (in shares)	1,008,519		1,008,519		1,013,103	980,339	678,232
Warrants outstanding, exercise price (in dollars per share)	$ 0.01		$ 0.01		$ 0.01	$ 0.01
Antidilutive securities (in shares)	7,599,975,000	7,255,385,000	7,599,975,000	7,255,385,000	8,337,653,000	7,002,258,000
$0.01 Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrants outstanding (in shares)	108,821	132,099	108,821	132,099	132,099	132,099
Warrants outstanding, exercise price (in dollars per share)	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	899,698,000	842,717,000	899,698,000	842,717,000	881,004,000	848,240,000
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	6,700,277,000	6,412,668,000	6,700,277,000	6,412,668,000	7,207,044,000	5,904,413,000
Performance awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)					249,605,000	249,605,000

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Nov. 12, 2013	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Feb. 19, 2020	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share appreciation rights		$ 741			$ 741		$ 706	$ 435
Unrecognized compensation expense, options		11,900			11,900		19,500	13,800
Total stock-based compensation expense		1,976	$ 2,545		3,701	$ 4,189	8,043	6,229
Unrecognized compensation expense		$ 1,000			$ 1,000		$ 1,200	$ 2,000
Number of Shares outstanding		6,700,277			6,700,277		7,207,044	5,904,413		5,565,292
Outstanding Shares exercise price per share		$ 4.75			$ 4.75		$ 4.94	$ 4.05		$ 2.88
Stock based compensation expense		$ 1,976	2,545		$ 3,701	4,189	$ 8,043	$ 6,229
Share based compensation arrangement,granted					0		2,328,385	1,135,148
Warrants issued to intermediaries							51,859	164,485
Warrants issued to investors								135,133
Fair value of warrants issued								$ 1,800
Number of additional warrants issued in period							0
Warrants issued for goods and services								5,246
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense		442	345		$ 851	767
Stock based compensation expense		$ 442	$ 345		$ 851	767
8.00% – 2020 Convertible Notes | Convertible Notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt instrument, stated percentage		8.00%			8.00%		8.00%		8.00%
Debt instrument, principal amount		$ 8,000			$ 8,000		$ 8,000		$ 8,000
5.00% – $25.0 Million Convertible Notes | Convertible Notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt instrument, stated percentage		5.00%			5.00%
Debt instrument, principal amount		$ 25,000			$ 25,000
Share Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share appreciation rights		$ 700			$ 700		$ 700	$ 400
Share-based compensation fair value (in dollars per share)		$ 24.70			$ 24.70		$ 20.28	$ 12.98
Vesting period	4 years
Number of Shares outstanding							30,000	30,000
Outstanding Shares exercise price per share							$ 0.00001	$ 0.00001
Share Appreciation Rights | Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense							$ 300	$ 20
Stock based compensation expense							$ 300	$ 20
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)		11,458,989			11,458,989		11,458,989
Number of shares available for grant (in shares)		3,088,276			3,088,276		2,746,089
Unrecognized compensation expense, period for recognition					1 year 2 months 12 days		1 year 4 months 24 days	1 year 3 months 18 days
Vesting period							4 years
Number of shares authorized for issuance		11,458,989			11,458,989		11,458,989
Number of shares available for grant		3,088,276			3,088,276		2,746,089
Percentage of options become exercisable on first anniversary of the grant							25.00%
Remaining options exercisable in equal monthly portions over the period							36 months
Total aggregate intrinsic value of options exercised							$ 100	$ 300
Weighted average grant date fair value of options,Granted							$ 8.32	$ 7.92
Performance Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense		$ 100		$ 200	$ 20	100	$ 800
Stock based compensation expense		$ 100		$ 200	$ 20	$ 100	$ 800
Weighted average grant date fair value of options,Granted								$ 7.84
Share based compensation arrangement,granted								249,605

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Options Outstanding
Beginning balance (in shares)	7,207,044	5,904,413	5,565,292
Options granted (in shares)	0	2,328,385	1,135,148
Options exercised (in shares)	(164,580)	(7,813)	(24,750)
Options forfeited (in shares)	(331,068)	(826,488)	(120,001)
Options expired (in shares)	(11,119)	(191,453)	(651,276)
Ending balance (in shares)	6,700,277	7,207,044	5,904,413	5,565,292
Options exercisable (in shares)	4,989,774	4,693,313
Average Exercise Price Per Share
Beginning balance (in dollars per share)	$ 4.94	$ 4.05	$ 2.88
Options granted (in dollars per share)	0	8.67	9.29
Options exercised (in dollars per share)	1.72	5.36	1.33
Options forfeited (in dollars per share)	10.30	8.62	6.65
Options expired (in dollars per share)	6.66	6.92	2.78
Ending balance (in dollars per share)	4.75	4.94	$ 4.05	$ 2.88
Options exercisable (in dollars per share)	$ 3.56	$ 3.16
Options outstanding, remaining contractual life	6 years 1 month 28 days	6 years 9 months	6 years 11 months 8 days	6 years 8 months 4 days
Options exercisable, remaining contractual life	5 years 3 months 21 days	5 years 6 months 3 days
Options outstanding, intrinsic value	$ 133,661	$ 110,552	$ 54,100	$ 59,146
Options exercisable, intrinsic value	$ 105,483	$ 80,334

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,976	$ 2,545	$ 3,701	$ 4,189	$ 8,043	$ 6,229
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	363	870	631	1,341	2,271	2,230
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,171	1,330	2,219	2,081	4,313	2,835
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 442	$ 345	$ 851	$ 767
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense					639	475
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense					$ 820	$ 689

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Fair Value Of Stock Options Valuation Assumptions And Methodology (Detail) - $ / pure	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility - Minimum	50.29%	50.40%
Expected volatility - Maximum	52.45%	51.37%
Risk-free interest rate - Minimum	0.30%	1.42%
Risk-free interest rate - Maximum	1.75%	1.88%
Fair value of Ordinary Shares - Minimum	10.58	13.21
Fair value of Ordinary Shares - Maximum	19.96	13.52
Dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	4 years 10 months 9 days	5 years 7 months 9 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 3 months	6 years 3 months

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Outstanding Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Warrants Outstanding
Beginning balance (in shares)	1,013,103	980,339	678,232
Warrants issued (in shares)	18,694	51,859	304,864
Warrants exercised (in shares)	(23,278)	(5,523)	(2,757)
Warrants cancelled (in shares)		(13,572)	0
Ending balance (in shares)	1,008,519	1,013,103	980,339
Average Exercise Price Per Share
Beginning balance (in dollars per share)	$ 7.33	$ 7.19	$ 7.05
Warrants issued (in dollars per share)	18.16	10.30	7.44
Warrants exercised (in dollars per share)	0	1.26	0
Warrants cancelled (in dollars per share)		11.44	0
Ending balance (in dollars per share)	$ 7.70	$ 7.33	$ 7.19
Weighted- Average Contractual Life (Years)	5 years 9 months 10 days	6 years 5 months 12 days	7 years 3 months 14 days	7 years 7 months 6 days

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Two Affiliate entities Of Directors | Consulting And Administrative Service
Related Party Transaction [Line Items]
Related party fee for services					$ 800,000	$ 1,900,000
Variable Interest Entity | HRT
Related Party Transaction [Line Items]
Sales to related parties	$ 0	$ 2,500,000	$ 0	$ 2,500,000	5,300,000	6,700,000
Accounts receivable, related parties, current	400,000		400,000		$ 3,300,000	$ 2,900,000
Accounts payable, related parties, current	$ 0		$ 0

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Operating Leased Assets [Line Items]
Operating lease, weighted average remaining lease term	3 years		3 years		3 years
Operating lease, weighted average discount rate	6.00%		6.00%		6.00%
Operating Lease Cost:
Fixed lease cost	$ 292	$ 213	$ 505	$ 426	$ 1,005	$ 1,030
Variable lease cost	36	81	119	121	154	253
Total operating lease cost	328	294	624	547	1,391	1,533
Fixed Lease Cost					851	777
Total	$ 292	$ 213	505	426	1,005	1,030
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases			462	454	916	756
Operating cash flows for finance leases			0	12	15	115
Principal payments on finance lease			0	933	1,192	1,215
Right-of-use assets obtained in exchange of lease obligations:
Right-of-use assets obtained in exchange for new operating lease liabilities			$ 2,187	$ 0	$ 0	$ 1,158
Operating lease,Option to extend					5
Operating lease, Option to extend , finance					5
Maximum [Member]
Right-of-use assets obtained in exchange of lease obligations:
Operaing lease,remaining lease term					4 years
Finance lease,remaining lease term					4 years
Minimum [Member]
Right-of-use assets obtained in exchange of lease obligations:
Operaing lease,remaining lease term					1 year
Finance lease,remaining lease term					1 year

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
2021 (for the remaining period)	$ 582
2022	1,239	$ 682
2023	931	613
2024	437	456
2025	327	121
Thereafter	394
Total lease obligation	3,910	1,872
Less: Imputed interest	(408)	(149)
Total lease liabilities	3,502	1,723
Less: Current lease liabilities	(1,020)	(596)
Total non-current lease liabilities	$ 2,482	$ 1,127

Commitment and Contingencies (D

Commitment and Contingencies (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Contractual obligations	$ 8.1	$ 3	$ 3.3

Defined Contribution Plan (Deta

Defined Contribution Plan (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Defined contribution plan, employer contributions	$ 0.2	$ 0.1	$ 0.4	$ 0.3	$ 0.5	$ 0.4

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Supplemental Cash Flow Information:
Interest paid			$ 271	$ 45	$ 47	$ 506
Income tax paid			210	80	313	352
Non-cash Operating Activities:
Right-of-use assets obtained in exchange for new operating lease liabilities			2,187	0	0	1,158
Total non-cash operating activities			2,187	0	0	1,158
Non-cash Investing Activities:
Right-of-use assets obtained in exchange of lease obligations			1,163	295
Unpaid property and equipment received					166	397
Unpaid Balance Related To The Trutouch Asset Acquisition					500	0
Total non-cash investing activities					666	397
Non-cash Financing Activities:
Unpaid deferred transaction costs			5,201
Forgiveness of Paycheck Protection Program loan	$ (2,900)	$ (2,860)	(2,860)	0
Conversion Of Note Payable To Ordinary Shares					0	18,244
Issuance of Ordinary Shares related to the Trutouch Asset Acquisition					2,298	0
NonCash Equity Issuance Costs					0	995
Non - cash dividend					0	1,838
Total non-cash financing activities			$ 2,341	$ 0	$ 2,298	$ 21,077

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	Aug. 12, 2021	Aug. 11, 2021	Mar. 19, 2021	Dec. 31, 2020	Aug. 09, 2021	Jun. 30, 2021	May 25, 2021	Feb. 19, 2021	Jan. 18, 2021	Jan. 13, 2021
Subsequent Event [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued In Period				250,000
2020 Term Facility Loan
Subsequent Event [Line Items]
Debt instrument, portion to be converted to equity							30.00%
Debt instrument, portion to be repaid							70.00%
Debt Instrument, Face Amount				$ 35		$ 35
Subsequent Event | Definitive Agreement [Member]
Subsequent Event [Line Items]
Proforma Enterprise Value			$ 1,200
Subsequent Event | Rockley Photonics Holdings Limited
Subsequent Event [Line Items]
Proceeds from sale of equity		$ 126.9
Subsequent Event | Rockley Photonics Holdings Limited | SC Health
Subsequent Event [Line Items]
Investment owned (in shares)		12,339,650
Percentage of outstanding shares held in investment		9.80%
Subsequent Event | Rockley Photonics Holdings Limited | Rockley Photonics Limited
Subsequent Event [Line Items]
Investment owned (in shares)		103,916,607
Percentage of outstanding shares held in investment		82.30%
Subsequent Event | 2020 Term Facility Loan
Subsequent Event [Line Items]
Debt instrument, portion to be converted to equity		30.00%
Debt instrument, portion to be repaid		70.00%
Debt Instrument, Face Amount								$ 11.4
Subsequent Event | Convertible Debt [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Subsequent Event | Convertible Debt [Member] | Five Percent Twenty Five Million Convertible Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount				$ 25
Subsequent Event | Convertible Debt [Member] | Five Percent Ten Million Convertible Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount										$ 10
Subsequent Event | Convertible Debt [Member] | Five Percent Thirty Million Convertible Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount									$ 30
Subsequent Event | The Business Combination
Subsequent Event [Line Items]
Business combination, conversion price per acquiree share (in dollars per share)					$ 10
Service fees incurred	$ 29.3
Unpaid professional fees	$ 14.8
Subsequent Event | The Business Combination | Rockley Photonics Holdings Limited
Subsequent Event [Line Items]
Business combination, conversion price per acquiree share (in dollars per share)					10
Subsequent Event | Rockley Photonics Limited
Subsequent Event [Line Items]
Business combination, conversion price per acquiree share (in dollars per share)					$ 10